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Abstract 32 
Polycomb repression in mouse embryonic stem cells (ESCs) is tightly associated with 33 
promoter co-occupancy of RNA polymerase II (RNAPII) which is thought to prime 34 
genes for activation during early development. However, it is unknown whether 35 
RNAPII poising is a general feature of Polycomb repression, or lost during 36 
differentiation. Here, we map the genome-wide occupancy of RNAPII and Polycomb 37 
from pluripotent ESCs to non-dividing functional dopaminergic neurons. We find that 38 
poised RNAPII complexes are ubiquitously present at Polycomb-repressed genes at 39 
all stages of neuronal differentiation. We observe both loss and acquisition of RNAPII 40 
and Polycomb at specific groups of genes reflecting their silencing or activation. 41 
Strikingly, RNAPII remains poised at transcription factor genes which are silenced in 42 
neurons through Polycomb repression, and have major roles in specifying other, non-43 
neuronal lineages. We conclude that RNAPII poising is intrinsically associated with 44 
Polycomb repression throughout differentiation. Our work suggests that the tight 45 
interplay between RNAPII poising and Polycomb repression not only instructs 46 
promoter state transitions, but may enable promoter plasticity in differentiated cells. 47 
 48 
Running title: Poising of RNAPII and Polycomb in neurons 49 
 50 
 51 
 52 
 53 
 54 
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Introduction 56 
Embryonic differentiation starts from a totipotent cell and culminates with the 57 
production of highly specialized cells. In ESCs, many genes important for early 58 
development are repressed in a state that is poised for subsequent activation (Azuara 59 
et al, 2006; Bernstein et al, 2006; Brookes et al, 2012; Stock et al, 2007). These genes 60 
are mostly GC-rich (Deaton & Bird, 2011) and their silencing in pluripotent cells is 61 
mediated by Polycomb repression complexes (PRCs). Genes with more specialized 62 
cell-type-specific functions are neither active nor Polycomb repressed in ESCs, have 63 
AT-rich promoter sequences, and their activation is associated with specific 64 
transcription factors (Brookes et al, 2012; Sandelin et al, 2007). 65 
 66 
PRC proteins have major roles in modulating gene expression during differentiation 67 
and in disease (Prezioso & Orlando, 2011; Richly et al, 2011). They assemble in two 68 
major complexes, PRC1 and PRC2, which catalyse H2AK119 monoubiquitination 69 
and H3K27 methylation, respectively (Simon & Kingston, 2013). Both PRC-mediated 70 
histone marks are important for chromatin repression, and synergise in a tight 71 
feedback loop to recruit each other’s modifying enzymes (Blackledge et al, 2015). 72 
Although imaging studies suggest that PRC-repressed chromatin has a compact 73 
conformation (Boettiger et al, 2016; Eskeland et al, 2010; Francis et al, 2004), 74 
molecular and cell biology approaches show that PRC repression in ESCs coincides 75 
with the occupancy of poised RNAPII complexes and active histone marks in the vast 76 
majority of PRC-repressed promoters (Azuara et al, 2006; Bernstein et al, 2006; 77 
Brookes et al, 2012; Kinkley et al, 2016; Stock et al, 2007; Tee et al, 2014; Weiner et 78 
al, 2016). The co-occurrence of RNAPII and PRC enzymatic activities, RING1B and 79 
EZH2, on chromatin have been confirmed in ESCs by sequential ChIP (Brookes et al, 80 
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2012), and is mirrored by the simultaneous presence of H3K4me3 and H3K27me3 81 
marks, called chromatin bivalency (Azuara et al, 2006; Bernstein et al, 2006; Kinkley 82 
et al, 2016; Sen et al, 2016; Voigt et al, 2012; Weiner et al, 2016). 83 
 84 
RNAPII function is regulated through complex post-translational modifications at the 85 
C-terminal domain (CTD) of its largest subunit, RPB1, which coordinate the co-86 
transcriptional recruitment of chromatin modifiers and RNA processing machinery to 87 
chromatin, leading to productive transcription events and mRNA expression (Brookes 88 
& Pombo, 2009; Zaborowska et al, 2016). In mammals, the CTD comprises 52 89 
repeats of the heptapeptide sequence N-Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7-C. At 90 
active genes, RNAPII is phosphorylated on Ser5 (S5p) to mark transcription 91 
initiation, on Ser7 (S7p) during the transition to productive transcription, and on Ser2 92 
(S2p) during elongation. S5p and S7p are mediated by CDK7 while S2p is mediated 93 
by CDK9. RNAPII also exists in a paused state of activation characterized by short 94 
transcription events at promoter regions, followed by promoter-proximal termination 95 
and re-initiation events (Adelman & Lis, 2012). RNAPII pausing is identified at genes 96 
that produce mRNA at lower levels, and is often measured as the ratio between the 97 
accumulation of RNAPII at gene promoters relative to its occupancy throughout 98 
coding regions. Paused states of RNAPII are therefore a feature of genes that are 99 
active to a lower extent, are characterized by the presence of S5p and S7p at gene 100 
promoters, low abundance of S2p throughout the coding regions, and they are 101 
recognised by 8WG16, antibody which has a preference for unphosphorylated Ser2 102 
residues. Paused RNAPII complexes are also characterized by methylation and 103 
acetylation of the non-canonical Lys7 residues at the CTD (Dias et al, 2015; Schroder 104 
et al, 2013; Voss et al, 2015).  105 
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 106 
RNAPII complexes found at PRC-repressed genes in mouse ESCs have a distinct 107 
configuration which is different from paused RNAPII, and was originally referred to 108 
as poised RNAPII (Brookes & Pombo, 2009; Stock et al, 2007). The poised RNAPII 109 
is characterized by exclusive phosphorylation of S5p in the absence of S7p, S2p, 110 
K7me1/2, K7ac, or recognition by 8WG16 (Brookes et al, 2012; Dias et al, 2015). 111 
Importantly, Ser5 phosphorylation of poised RNAPII complexes at Polycomb 112 
repressed genes is mediated by different kinases, ERK1/2 (Ma et al, 2016; Tee et al, 113 
2014), instead of CDK7 which phosphorylates both S5p and S7p at active genes, 114 
irrespectively of pausing ratio (Akhtar et al, 2009; Glover-Cutter et al, 2009). Loss of 115 
ERK1/2 activity in ESCs results in the loss of RNAPII-S5p and decreased occupancy 116 
of PRC2 at Polycomb-repressed developmental genes (Tee et al, 2014), suggesting a 117 
tight functional link between the presence of poised RNAPII-S5p and the recruitment 118 
of Polycomb repression to its target genes.  119 
 120 
The poised RNAPII-S5p state has so far been studied at Polycomb-repressed genes in 121 
ESCs. However, it is also important to note that RNAPII occupancy at Polycomb-122 
target genes, together with EZH2 and H3K27me3 levels, are reduced upon growth of 123 
ESCs in 2i conditions (Marks et al, 2012; Williams et al, 2015), which aim to simulate 124 
a more naïve state of pluripotency by inhibition of GSK3 and MEK signalling, which 125 
in turn inhibits ERK signalling. However prolonged 2i treatment has recently been 126 
shown to impair ESC developmental potential and to cause widespread loss of DNA 127 
methylation (Choi et al, 2017; Yagi et al, 2017), renewing the interest in 128 
understanding the regulation of developmental genes, and the interplay between 129 
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poised RNAPII complexes and Polycomb repression mechanisms, in growth 130 
conditions that can support a pluripotent state whilst avoiding 2i conditions. 131 
 132 
While histone bivalency has been studied to some extent during cell differentiation 133 
and found present at smaller proportion of genes (Lien et al, 2011; Mohn et al, 2008; 134 
Wamstad et al, 2012; Xie et al, 2013), it remains unexplored whether the co-135 
occupancy of poised RNAPII-S5p at PRC targets is a property of ESCs or extends 136 
beyond pluripotency. Recent studies of DNA methylation in differentiated tissues 137 
show that many silent developmental regulator genes remain hypomethylated in wide 138 
genomic regions regions (also called DNA methylation valleys) in differentiated 139 
tissues (Xie et al, 2013), raising the question of whether poised RNAPII complexes 140 
might prime developmental regulator genes in the cell lineages irrespectively of future 141 
activation. In this scenario, Polycomb repression may represent the universal mode of 142 
repression of this group of CpG-rich genes that recruit poised RNAPII-S5p and which 143 
are not targeted by DNA methylation. Silencing of developmental regulator genes 144 
through Polycomb-repression mechanisms in fully differentiated cells, especially in 145 
the presence of poised RNAPII complexes, may nevertheless have roles in the 146 
remodelling of cell function, for example in response to specific stimuli such as tissue 147 
injury, or in disease such as in cancers associated with Polycomb dysfunction. 148 
 149 
To investigate RNAPII poising at Polycomb-repressed genes from pluripotency to 150 
terminal differentiation, we mapped H3K27me3 (a marker of Polycomb repression), 151 
RNAPII-S5p (present at both active and poised RNAPII complexes) and RNAPII-S7p 152 
(a marker of productive gene expression), and produced matched mRNA-seq datasets, 153 
in ESCs and in four stages of differentiation of functionally mature dopaminergic 154 
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neurons. We show compelling evidence that the presence of poised RNAPII at 155 
H3K27me3-marked chromatin is not a specific feature of ESCs, but a general 156 
property common to differentiating and post-mitotic cells. We also observe de novo 157 
Polycomb repression during neuronal cell commitment and neuronal maturation that 158 
promotes waves of transient down-regulation of gene expression. We discover a 159 
group of genes that maintain RNAPII-S5p poising and Polycomb silencing throughout 160 
neuronal differentiation, and which are developmental transcription factors important 161 
for cell specification towards non-neuronal lineages. Although these genes are 162 
unlikely to be subsequently reactivated in the neuronal lineage, their repression is 163 
sensitive to Polycomb inhibition or knockout in both neuronal precursors and mature 164 
neurons. We show that the presence of RNAPII-S5p at specific subsets of Polycomb-165 
repressed genes in terminally differentiated neurons coincides with their wide 166 
hypomethylation in mouse brain. Our study reveals the interplay between RNAPII 167 
poising and Polycomb repression in the control of regulatory networks and cell 168 
plasticity throughout cell differentiation, which advances our understanding of 169 
different silencing mechanisms at play in differentiated cells and is likely important 170 
for cell fate remodelling in development and disease. 171 
 172 
Results 173 
 174 
Capturing distinct stages of differentiation from ESCs to dopaminergic neurons 175 
To study the dynamic changes in Polycomb and RNAPII occupancy at gene 176 
promoters during differentiation, we optimised neuronal differentiation protocols to 177 
obtain large quantities of pure cell populations required for mapping chromatin-178 
associated histone marks and RNAPII at five states of differentiation towards the 179 
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neuronal lineage specification that leads to the production of functional dopaminergic 180 
neurons (ESC, days 1, 3, 16 and 30; Fig 1A). To capture the early exit from 181 
pluripotency, we adopted an approach that starts from mouse ESCs grown in serum-182 
free conditions and achieves synchronous exit from pluripotency within three days 183 
towards the production of neuronal progenitors (Abranches et al, 2009); Fig EV1A, 184 
top row). To obtain terminally differentiated dopaminergic neurons, we used a 185 
different approach that commits ESCs to a midbrain neuron phenotype (Jaeger et al, 186 
2011); Fig EV1A, bottom row).  187 
 188 
The expression of pluripotency markers Nanog and Oct4 decreases dramatically at 189 
days 1 and 3 of differentiation, respectively (Fig 1B). The early differentiation marker 190 
Fgf5 is transiently expressed in days 1 to 3, whereas neuronal markers Blbp, Hes5 and 191 
Mash1/Ascl1 are increasingly expressed from day 2 (Fig 1B and Fig EV1B). The 192 
expression of Sox2, which encodes for a transcription factor expressed in ESCs and by 193 
most central nervous system progenitors (Graham et al, 2003), is detected from ESC 194 
to day 4, as expected (Fig EV1B; (Abranches et al, 2009). After sixteen days, we 195 
obtained neurons that no longer express OCT4 protein, are positive for the neuronal 196 
marker TUBB3 (detected by Tuj1 antibody), and no longer divide, as assessed by lack 197 
of BrdU incorporation into newly replicated DNA (Fig 1C).  198 
 199 
To confirm the dopaminergic phenotype, we performed immunofluorescence for 200 
tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis (Fig 1D). 201 
The neuronal populations obtained expressed TH from day 16, reaching close to 202 
ubiquitous expression at day 30 (Fig 1D). Moreover, 70% of cells co-express LMX1A 203 
and FOXA2 at day 16 (Fig EV1C), two markers specific to the dopaminergic ventral 204 
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midbrain, confirming that the neuronal populations produced are highly enriched for 205 
the dopaminergic lineage (Hegarty et al, 2013). Taken together, these results indicate 206 
that day 16 neurons represent an immature stage of differentiation committed to the 207 
ventral midbrain lineage, which further mature until day 30. 208 
 209 
To characterize the changes in gene expression that accompany neuronal 210 
differentiation, we produced mRNA-seq datasets for ESCs, day 1, day 3, day 16 and 211 
day 30. We identified 4656 genes whose expression levels peaked at one specific time 212 
point (Fig 1E). Genes peaking in ESCs are enriched in Gene Ontology (GO) terms 213 
typical of pluripotency, such as ‘stem cell maintenance’, ‘regulation of gene 214 
silencing’ and ‘sugar utilization’, and include Nanog, Tet1 and Hk2. Genes with 215 
highest expression on day 1 have roles in the exit from pluripotency, such as Wt1, 216 
Foxd3 and Dnmt3b, and are enriched in GO terms ‘cell morphogenesis’, ‘pattern 217 
specification process’ and ‘gene silencing’. On day 3, the expression of Fgf8, Gli3 218 
and HoxA1 peaked, reflecting an early stage of neuronal commitment, highlighted by 219 
enrichment in GO terms such as ‘cellular developmental process’, ‘multicellular 220 
organismal process’ and ‘neuronal nucleus development’. Day 16 coincided with 221 
highest expression of genes associated with GO terms such as ‘nervous system 222 
development’, ‘axon guidance’ and ‘neuron migration’ (including Nova1, Sema3f, 223 
Ascl1, Neurog2), and day 30 with genes important for dopaminergic synaptic 224 
transmission, for the‘G-protein coupled receptor protein signalling pathway’ and 225 
‘response to alkaloid’ (such as Lpar3, Th, Park2, Chrnb4). The complete list of 226 
enriched GO terms is presented in Dataset EV1. These expression profiles show that 227 
each time point captures a specific stage of neuronal development, and suggest that 228 
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days 16 and 30 reflect early and late stages, respectively, of maturation of 229 
dopaminergic neurons. 230 
 231 
To further confirm the quality of our samples, we also explored the expression 232 
profiles of specific single genes (Fig EV2). In addition to confirming the expression 233 
of the differentiation markers studied by quantitative PCR and immunofluorescence 234 
(Fig EV2A), we also found that the proneural gene Ngn2 (expressed in immature but 235 
not in mature dopaminergic neurons) peaks at day 16 and drops by day 30, while 236 
Nurr1 (required for maintenance of dopaminergic neurons) is upregulated at day 16 237 
but remains expressed at day 30 (Fig EV2B; (Ang, 2006). Other markers of 238 
dopaminergic neurons, such as Pitx3, Aadc, Vmat and Dat, are most highly expressed 239 
at day 30 (Fig EV2B). 240 
 241 
Electrophysiological measurements demonstrate distinct stages of neuronal 242 
maturation on days 16 and 30 of differentiation 243 
To directly investigate the state of maturation of neurons upon prolonged culture, we 244 
measured their action potential activity and synaptic connectivity by conducting 245 
targeted whole-cell electrophysiological recordings (Fig 2A) at four different time 246 
points (days 14-16, 20-25, 26-30 and >30). We find that days 14-16 neurons are 247 
largely silent, whereas at days >30 they exhibit robust spontaneous action potential 248 
activity (Fig 2B and Fig EV3A), similar to the activity of midbrain dopaminergic 249 
neurons from ex vivo slice preparations and in vivo (Marinelli & Mccutcheon, 2014). 250 
During maturation, neurons also exhibit a hyperpolarisation-activated inward (Ih) 251 
current (Fig 2C), an electrophysiological feature commonly used to identify 252 
dopaminergic neurons (Ungless & Grace, 2012). Strikingly, after prolonged culture 253 
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many cells exhibit burst-like events (Fig EV3B and C), often seen in vivo in midbrain 254 
dopaminergic neurons (Grace & Bunney, 1984), which are thought to be driven in 255 
part by synaptic inputs (Paladini & Roeper, 2014). We also observed maturation of 256 
functional synaptic connectivity. Spontaneous synaptic events were rare at days 14-257 
16, but were present in most neurons from days 20-25 onwards (Fig 2D and E). 258 
Further experiments in the presence of TTX (which blocked action potential activity; 259 
Fig EV3D) revealed the presence of glutamatergic AMPA-receptor-mediated 260 
miniature excitatory postsynaptic currents (mEPSCs; Fig EV3E) and GABAA-261 
receptor-mediated miniature inhibitory postsynaptic currents (mIPSCs; Fig EV3F), 262 
similar to those seen in ex vivo dopaminergic neurons. Consistent with this, we also 263 
observed a small number of GABAergic and glutamatergic neurons in our cultures 264 
(Fig EV3G), as seen in the ventral tegmental area (VTA) of the midbrain in vivo, and 265 
expression of GABAergic and glutamatergic neuronal markers (Fig EV3H). Further 266 
evidence in support of the quality of our neuronal samples was the absence of 267 
glutamatergic autapses (Fig EV3I), which are seen in cultured ex vivo dissociated 268 
neurons, but not in ex vivo brain slices (Sulzer et al, 1998). 269 
 270 
We conclude that the neuronal differentiation approach established here yields 271 
functional neurons that undergo progressive maturation, as shown by their action 272 
potential activity and synaptic connectivity. Taken together, gene expression and 273 
electrophysiological analyses confirm that the five time points used here represent 274 
distinct stages of neuronal fate commitment and maturation.  275 
 276 
Polycomb repression dynamics during terminal differentiation of dopaminergic 277 
neurons 278 
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To identify the genes regulated by Polycomb during neuronal specification, we 279 
mapped the genome-wide occupancy of H3K27me3, the PRC2-mediated histone 280 
modification. In ESCs grown in serum-free conditions, 4107 genes are marked by 281 
H3K27me3 (Fig 3A), most of which (78-86%) were also found targeted by PRC in 282 
ESCs in serum-containing media (Brookes et al, 2012; Lienert et al, 2011; Young et 283 
al, 2011), demonstrating the important roles of Polycomb repression mechanisms in 284 
ESCs independent from the use of serum and concerns of premature differentiation.  285 
 286 
Upon early exit from the pluripotent state, the number of H3K27me3+ genes increases 287 
to 4600 in days 1 and 3, before decreasing to 2200 genes in days 16 and 30 (Fig 288 
3A). The abundance of PRC-marked promoters in dopaminergic neurons suggests an 289 
important role of Polycomb repression in differentiated cells, which is consistent with 290 
previous reports in other specialised cell types: pyramidal glutamatergic neurons 291 
(2178 genes; (Mohn et al, 2008), striatal GABAergic neurons (2057 genes; (von 292 
Schimmelmann et al, 2016), functional endocrine cells (1273 genes; (Xie et al, 2013) 293 
and in E12.5 heart ventricle apex (1052 genes; (He et al, 2012). 294 
 295 
To study the dynamics of Polycomb repression across the different stages of 296 
differentiation, we grouped promoters according to H3K27me3 presence or absence 297 
(Fig 3B). H3K27me3 marks a total of 5672 genes in at least one time point (Dataset 298 
EV2). Over half of the H3K27me3+ genes in ESCs lose H3K27me3 between days 1 299 
and 30 (‘PRC lost’ genes), while 1408 genes remain H3K27me3+ throughout the 300 
differentiation timeline (‘PRC maintained’; Fig 3C). Genes that lose H3K27me3 301 
include Fos, Zic1, Ncam1 and Wnt5a, and are enriched in GO terms such as ‘nervous 302 
system development’, ‘regulation of signalling’ and ‘cell adhesion’, consistent with 303 
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their activation upon acquisition of the neuronal phenotype. Genes associated with 304 
PRC in all time points include developmental transcription factors such as Nkx2-5, 305 
Pax6 and Gata4, and are enriched in functions such as ‘anatomical structural 306 
development’, ‘pattern specification process’, ‘regulation of cell differentiation’ and 307 
‘DNA dependent transcription’. De novo acquisition of H3K27me3 is detected 308 
throughout differentiation (‘PRC acquired’ genes), with a transient appearance of 309 
H3K27me3 at 931 genes between days 1 and 3, and at 351 genes in post-mitotic 310 
neurons (Fig 3C). These genes are enriched in GO terms such as ‘regulation of cell 311 
proliferation’, and include important signalling regulators as Nodal, Notch1 and Fzd5. 312 
Our results show that genes targeted by PRC during neuronal differentiation undergo 313 
dynamic changes at appropriate stages of differentiation. 314 
 315 
Poised RNAPII-S5p is present at H3K27me3+ promoters throughout differentiation  316 
To investigate whether poised RNAPII-S5p is lost from Polycomb-repressed 317 
promoters upon exit from pluripotency, or associated with Polycomb throughout 318 
terminal differentiation, we produced ChIP-seq datasets for RNAPII-S5p and 319 
RNAPII-S7p in ESCs and at days 1, 3, 16 and 30 (Fig 4A). Inspection of single-gene 320 
profiles revealed different promoter states and dynamic changes (Fig 4B). For 321 
example, the housekeeping gene Eif2b2 is always expressed at the mRNA level and 322 
occupied by RNAPII-S5p and S7p, whereas testis-specific Brs3 is always inactive and 323 
lacks H3K27me3 and RNAPII throughout our differentiation timeline. In contrast, 324 
Adcy5, a gene implicated in axonal elongation and in addiction (del Puerto et al, 2012; 325 
Procopio et al, 2013), is marked by RNAPII-S5p and H3K27me3 in ESCs and 326 
becomes Active from day 16, acquiring S7p, losing H3K27me3 and maintaining S5p. 327 
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Pkp1, which has roles in epidermal morphogenesis (South et al, 2003), is always 328 
marked by H3K27me3, but associated with poised RNAPII-S5p only in ESCs and in 329 
early differentiation. Notably, Pitx1, a transcription factor with roles in limb 330 
morphogenesis (Infante et al, 2013), is marked by RNAPII-S5p and H3K27me3 at all 331 
five time points, without S7p or mRNA expression. Examples of de novo PRC 332 
repression include Ajuba, a gene implicated in cell-cycle progression (Hirota et al, 333 
2003) which is downregulated during differentiation while acquiring H3K27me3, and 334 
retaining S5p, S7p and low levels of mRNA expression. Genes marked with 335 
H3K27me3, RNAPII-S5p and RNAPII-S7p in bulk ChIP assays have been previously 336 
described in ESCs and shown to correspond to promoter fluctuations between active 337 
and PRC-repressed states in different cells or alleles (Brookes et al, 2012; Kar et al, 338 
2017). 339 
 340 
For an unbiased exploration of the transitions between states of Polycomb repression 341 
and productive transcription across differentiation, we classified promoters according 342 
to the presence or absence of RNAPII-S5p (marker of both active and PRC-repressed 343 
promoters), RNAPII-S7p (only at active promoters) and H3K27me3 (PRC-repressed 344 
promoters). As previously reported, most promoters marked by H3K27me3 in ESCs 345 
are also bound by RNAPII-S5p (81%; Fig 4C; (Brookes et al, 2012). Importantly, we 346 
find that this association is maintained throughout differentiation, showing that 347 
RNAPII poising at PRC-marked promoters is a general property of Polycomb 348 
repression and not only specific to ESCs. We find that PRC/S5p genes are 349 
increasingly marked by RNAPII-S7p (Fig 4D) and expressed at the mRNA level (Fig 350 
4E) during terminal differentiation, suggesting a role for PRC repression not limited 351 
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to strict gene silencing, but also in modulating gene expression levels, as seen 352 
previously in ESCs (Brookes et al, 2012; Kar et al, 2017). 353 
 354 
Genome-wide transitions in Polycomb repression states 355 
To understand the dynamic transitions in promoter states throughout differentiation, 356 
we classified genes according to the presence of RNAPII-S5p, -S7p and H3K27me3, 357 
in each time point (Fig 5A). PRC-positive promoters were classified as ‘PRC Only’ 358 
(H3K27me3+S5p–S7p–), as ‘PRC/S5p’ (H3K27me3+S5p+ S7p–) and as ‘PRC/Active’ 359 
(H3K27me3+S5p+S7p+). PRC-negative promoters were classified as ‘Active’ 360 
(H3K27me3–S5p+S7p+), or as ‘Inactive’ (H3K27me3–S5p–S7p–). The other three 361 
combinations of promoter marks (S7p Only, S5p Only, and PRC/S7p) were 362 
uncommon and not explored further in the present study. The numbers of genes in 363 
each state are summarized in Fig EV4A; gene promoter states are listed in Dataset 364 
EV2. We found that the decrease in the number of promoters marked by PRC is 365 
accompanied by an increase in Active promoters, whilst the number of Inactive 366 
promoters remains stable (Fig 5B). The decrease in PRC-positive promoters occurs 367 
across all PRC classes, except for a relative increase in the PRC/Active state (Fig 5B). 368 
By following the changes in promoter state between time points (Fig EV4B), we 369 
show that the increase in the Active promoter state in days 16 and 30 originates 370 
mostly from genes that were PRC repressed in ESCs to day 3; this transition is 371 
accompanied by increased mRNA expression, as expected from the acquisition of S7p 372 
and loss of H3K27me3 at this group of genes (Fig EV4C). These newly Active genes 373 
have specific neuronal functions (Fig EV4D).  374 
 375 
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Next, we investigated the promoter state transitions of the genes which are poised by 376 
PRC/S5p in ESCs (Fig 5C). Many of the PRC/S5p genes in ESCs become Active 377 
(743/1913) or PRC/Active (580/1913) in day 30, and have functions in cell polarity or 378 
synaptic activity. Acquisition of S7p is accompanied by increased mRNA expression, 379 
as expected (Fig 5D). Notably, a group of PRC/S5p genes in ESCs display the poised 380 
conformation also in day 30 neurons (200/1913 genes; Fig 5C). Importantly, these 381 
genes are developmental transcription factors (TFs) which regulate non-neuronal cell 382 
lineages (e.g. Gata4, Pax7, Nkx3-2). We also find PRC/S5p genes that resolve to 383 
Inactive (129/1913), with functions in ‘germ cell development’, or that become PRC 384 
Only (236/1913), with functions including ‘Wnt signalling’. 385 
 386 
Other interesting Polycomb-dependent transitions in promoter activation states are 387 
those that result in de novo acquisition of H3K27me3 in either days 1/3 or days 16/30 388 
(Fig EV5A and B). Most genes that gain H3K27me3 in days 1 or 3 tend to be Active 389 
in ESCs, and go back to their original promoter state in day 30, with the acquisition of 390 
H3K27me3 in days 1/3 being accompanied by a decrease in gene expression (Fig 391 
EV5A). The genes that acquire PRC at days 16 or 30 also tend to be Active in ESCs 392 
and to be downregulated when acquiring H3K27me3 (Fig EV5B).  393 
 394 
Taken together, our results show a role for Polycomb in the silencing of non-neuronal 395 
TFs in neurons and in fine-tuning gene expression states during differentiation, which 396 
is often accompanied by poised RNAPII-S5p complexes. 397 
 398 
 399 
 400 
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H3K27me3 chromatin is co-occupied with RNAPII-S5p complexes in mature 401 
neurons 402 
To test the simultaneous occupancy of RNAPII-S5p and H3K27me3 at Polycomb-403 
repressed genes in terminally differentiated neurons, we performed sequential ChIP 404 
(or re-ChIP; Fig 5E). We immunoprecipitated chromatin from day 30 neurons with 405 
the antibody used to map RNAPII-S5p, before re-immunoprecipitation with different 406 
antibodies. We show that the promoter of the Active gene Actb is co-bound by 407 
RNAPII-S5p and RNAPII-S7p, but not by H3K27me3, as expected (Fig 5F). 408 
Notably, Pitx1 and Gata4 promoters, which are classified as PRC/S5p in all time 409 
points, are co-occupied by H3K27me3 and RNAPII-S5p, but not RNAPII-S7p. These 410 
results show that RNAPII-S5p and H3K27me3 simultaneously occupy Polycomb-411 
repressed promoters in mature dopaminergic neurons, as previously shown for ESCs 412 
(Brookes et al, 2012). We also tested the co-association of H3K27me3 with RNAPII-413 
S5p at Skap2 and Ajuba, which are PRC/Active genes that acquire H3K27me3 de 414 
novo in day 30, and found that H3K27me3 and RNAPII-S5p also co-localise at these 415 
promoters. In agreement with the PRC/Active classification, RNAPII-S5p co-416 
immunoprecipitates with RNAPII-S7p, consistent with the presence of the active 417 
(S5p+S7p+) form of RNAPII at some alleles or in different cells (Brookes et al, 2012). 418 
None of the marks tested were enriched at the inactive gene (Myf5), confirming the 419 
specificity of the assay. Re-ChIP with an unrelated antibody, against plant steroid 420 
digoxigenin, was used as a negative control to confirm minimal antibody carry-over 421 
from the first to the second immunoprecipitation. The sequential ChIP analyses 422 
performed here in terminally differentiated neurons show that RNAPII poising is 423 
present at PRC repressed genes also in post-mitotic neurons.  424 
 425 
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Poised PRC/S5p promoter states are associated with increased potential for 426 
reactivation upon Polycomb knockout or chemical inhibition 427 
 428 
To explore the biological relevance of the poised PRC/S5p promoter state, we 429 
investigated the effect of Polycomb knockout at PRC/S5p genes compared to PRC 430 
Only genes. First, we took advantage of published transcriptome resources in ESCs 431 
which measured transcriptional derepression after stable knockout of PRC2 432 
component Eed or conditional knockout of the major PRC2 enzymatic activity 433 
Ring1B in Ring1A-/- background (Cruz-Molina et al, 2017; Endoh et al, 2008). We 434 
find that a larger proportion of PRC/S5p genes are upregulated in both PRC knockout 435 
cell lines, compared to PRC Only genes (Fig 6A). Only a small fraction of Active and 436 
Inactive genes respond to PRC knockout, which may arise through more indirect 437 
regulatory effects associated with adaptation in the knockout cell lines.  438 
 439 
Second, we performed similar analyses using a published microarray dataset from an 440 
in vivo PRC2 knockout in GABAergic striatal medium spiny neurons (von 441 
Schimmelmann et al, 2016). Although the neuronal subtypes are not fully matched 442 
between the promoter state classification from our neuronal cultures, that simulate the 443 
ventral tegmental area, and the GABAergic neurons from the striatum, we find that 444 
most genes up-regulated upon PRC2 loss in ex vivo striatal neurons have the 445 
PRC/S5p promoter state in our mature day 30 neurons (52 out of the total 150 446 
upregulated genes; hypergeometric test for enrichment, p= 3.1x10-56; of note, 39 of 447 
those are PRC/S5p at all stages; Fig 6B). In contrast, only 17 genes upregulated in the 448 
striatal neurons are classified as PRC Only in the dopaminergic cultures (p= 6.8x10-7), 449 
and a smaller proportion of Active or Inactive genes become upregulated. These 450 
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results suggest that the PRC/S5p state leads to increased derepression upon Polycomb 451 
loss in both ESCs and differentiated neurons, which has implications for our 452 
understanding of Polycomb roles in maintaining cell type and cell differentiation 453 
states. 454 
 455 
Lastly, we tested the response of PRC/S5p and PRC Only genes to PRC2 enzymatic 456 
inhibition at three different stages of differentiation (ESC, day 3 and day 30). We used 457 
UNC1999, a chemical drug that blocks the enzymatic activity of both EZH1 and 458 
EZH2 (Konze et al, 2013), in two concentrations (1 and 3 µM), and measured relative 459 
RNA levels by quantitative PCR. We tested six genes that maintain the PRC/S5p state 460 
throughout the differentiation (Tal1, Gata4, Skor1, Pitx1, HoxA7 and Mesp1), three 461 
genes that are PRC/S5p in ESCs but become PRC Only from day 3 onwards (Pouf3, 462 
Pkp1, She) and three genes that maintain the PRC Only promoter state throughout 463 
differentiation (Fam150b, Fgf20, Chdrl2). We find that five out of the six PRC/S5p 464 
genes that maintain their state are upregulated upon enzymatic inhibition of PRC2, 465 
with increased derepression at the higher inhibitor concentration (Fig 6C). In contrast, 466 
none of the analysed genes acquiring or maintaining the PRC Only state show 467 
detectable RNA levels or respond to EZH1/2 inhibition at either UNC1999 468 
concentration in any of the three time points tested. Quality of PCR primers was 469 
verified by agarose gel electrophoresis (Appendix Fig 1).  470 
 471 
Taken together, these results suggest that the poised RNAPII-S5p is associated with 472 
increased potential for reactivation upon loss of Polycomb repression in ESCs and in 473 
differentiated cells at different stages of maturation, including terminally 474 
differentiated neurons both in vitro and in vivo. 475 
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 476 
Major non-neuronal transcription factors maintain PRC/S5p occupancy upon 477 
terminal differentiation 478 
To investigate further the significance of the poised PRC/S5p promoter state during 479 
neuronal cell commitment, we focused on 115 genes that maintain the PRC/S5p state 480 
during all the sampled stages of neuronal differentiation (Fig 7A). For comparison, 481 
we chose two other groups of genes which are also PRC/S5p in ESCs but remain 482 
silent in neurons through other promoter states; one group becomes PRC Only (losing 483 
S5p; 127 genes) and the other becomes Inactive (losing both H3K27me3 and S5p; 92 484 
genes; Fig 7A and Fig EV6A). Average profiles of H3K27me3 and RNAPII-S5p 485 
occupancy show that these three groups of genes are clearly marked by both 486 
H3K27me3 and RNAPII-S5p in ESCs (Fig 7B; (Brookes et al, 2012). The genes that 487 
maintain the PRC/S5p promoter state throughout neuronal differentiation have similar 488 
S5p occupancy at their promoters and throughout the coding region in ESCs, but 489 
show higher average levels of H3K27me3 occupancy in comparison with genes that 490 
resolve to PRC Only or Inactive (Fig 7B). We noticed that the PRC/S5p genes that 491 
maintain their state during neuronal differentiation are associated with wider regions 492 
of H3K27me3 occupancy compared to genes that lose RNAPII-S5p or to all other 493 
neuronal H3K27me3+ promoters in both ESCs and day 30 neurons (Fig 7B-D).  494 
 495 
To explore the biological relevance of the three groups of genes, we performed GO 496 
enrichment analyses (Fig EV6B). Interestingly, the group of 115 PRC/S5p genes that 497 
maintain their state is enriched in TFs important for non-neuronal lineages such as 498 
Gata4, Mesp1, Tbx2 (GO term: 'heart morphogenesis'), Barx1, Gata6, Hoxb5  499 
('epithelial cell differentiation'), and Osr2, Pax1, Tcfap2a ('bone morphogenesis'), 500 
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suggesting a role for the poised PRC/S5p state in terminally differentiated neurons in 501 
maintaining cell identity and plasticity by repressing non-neuronal genes.  502 
 503 
 504 
 505 
Key non-neuronal transcription factors that maintain the PRC/S5p state in neurons 506 
have high CpG content 507 
Polycomb occupancy in ESCs is highly correlated to CpG content (Deaton & Bird, 508 
2011; Ku et al, 2008) and unmethylated CpGs (Sen et al, 2016). To test whether the 509 
retention of the PRC/S5p state throughout neuronal differentiation is related with high 510 
CpG content, we measured the proportion of the promoter regions covered by CpG 511 
islands, the GC content of TSSs and the extent of CpG island coverage of gene 512 
bodies. We observe that the promoter of PRC/S5p genes that maintain the poised state 513 
in neurons are more extensively covered by CpG islands than the genes that become 514 
PRC Only or Inactive (Fig 7E). Their promoter GC content is also higher (Fig EV6C) 515 
and the CpG islands cover longer portions of gene body (Fig EV6D) than at genes 516 
that become Inactive. These results suggest that Polycomb repression in co-517 
association with poised RNAPII-S5p correlates with specific sequence features of 518 
gene promoters and gene bodies, namely with high CpG content.  519 
 520 
Key non-neuronal transcription factors that maintain the PRC/S5p state in neurons 521 
are located in DNA methylation valleys 522 
Previous reports have identified wide depletions of DNA methylation (DNA 523 
methylation valleys or DMVs; longer than 5kb) in different cell lineages, which 524 
coincide with CpG-rich regions often located at loci encoding for developmental 525 
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transcription factors (Xie et al, 2013). To explore the association of genes that 526 
maintain the poised PRC/S5p conformation throughout differentiation with DMVs, 527 
we mined a published dataset for DNA methylation from mouse frontal cortex (Lister 528 
et al, 2013), and classified DMVs (Xie et al, 2013). Visual inspection of single gene 529 
profiles shows that the regions occupied by H3K27me3 and RNAPII-S5p in neurons 530 
often coincide with large stretches of hypomethylated DNA, as shown for Pitx1 (Fig 531 
7F). Expanding these observations genome-wide, we find that all PRC/S5p gene 532 
promoters that maintain their poised state throughout neuronal differentiation are 533 
hypomethylated in mouse cortex, with the majority (65%; 70/115) overlapping with 534 
DMVs (Fig 7G). In contrast, only 13% (16/127) of the promoter of genes that become 535 
PRC Only or 2% (2/92) of genes that become Inactive reside in DMVs. Therefore, the 536 
maintenance of the PRC/S5p state is a property of important developmental 537 
transcription factors that are also rich in CpG and lack DNA methylation in terminally 538 
differentiated tissues.  539 
 540 
Maintenance of PRC/S5p state occurs at the promoters of developmental 541 
transcription factors that are candidate drivers of trans-differentiation  542 
The observation that key developmental TFs are repressed in post-mitotic neurons 543 
through Polycomb repression in the presence of poised RNAPII-S5p led us to 544 
hypothesize whether this conformation could contribute to make the genome 545 
permissive to trans-differentiation of neurons to other cell types. To explore this 546 
hypothesis, we took advantage of a predictive system, Mogrify, of the TFs necessary 547 
to induce cell type reprogramming, which combines gene expression data with 548 
regulatory network information (Rackham et al, 2016); Fig 8A). We overlapped the 549 
TFs that Mogrify predicts to be important for trans-differentiation to various cell fates 550 
  
23 
with the promoter states that we have identified in day 30 neurons. We find that the 551 
Mogrify lists of candidate genes for trans-differentiation towards non-neuronal 552 
lineages, such as cardiomyocytes, skin fibroblasts and skeletal muscle, are 553 
significantly enriched in genes marked by H3K27me3 in day 30 neurons, and 554 
especially in genes with the poised PRC/S5p promoter state (Fig 8B; for additional 555 
examples see Fig EV7A). In contrast, the Mogrify lists of reprogramming TFs are 556 
depleted of genes that have Inactive promoter states in day 30 neurons. We also 557 
investigated the lists of reprograming TFs predicted to be important for trans-558 
differentiation to neuronal lineages, including to hippocampus, neuron or brain. These 559 
genes are more often Active or PRC/Active in day 30 neurons, as expected due to 560 
their expression in the neuronal lineage, or alternatively associated with poised 561 
PRC/S5p promoter state (Fig 8B).  562 
 563 
Mogrify also ranks TFs according to their importance for trans-differentiation when 564 
they are predicted to regulate a larger number of the genes required to drive changes 565 
in phenotype; these gene are scored as having high influence on trans-differentiation. 566 
In contrast, the genes that are found to be less important for trans-differentiation (and 567 
scored as low influence) tend to be less connected or to regulate genes that are less 568 
specific to the target cell type (see schematic in Fig 8C). To test whether genes in 569 
different states of Polycomb repression are enriched amongst the highest or lowest 570 
influence TFs, we used Gene Set Enrichment Analysis (GSEA). Interestingly, we find 571 
that genes that have Active promoter states in day 30 neurons are significantly 572 
enriched for low influence TFs (False Discovery Rate <25%), whereas poised 573 
PRC/S5p genes are significantly enriched in high influence TFs that are candidates to 574 
promote conversions towards non-neuronal cell fates (Fig 8D; see example in Fig 575 
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EV7B). These results show that H3K27me3 and RNAPII-S5p mark silent genes in 576 
neurons which are predicted to be important to promote trans-differentiation to non-577 
neuronal lineages, suggesting a role of the poised state in allowing cell identity 578 
conversions and of Polycomb repression in stabilizing specific differentiated states. 579 
 580 
Discussion 581 
Most genes repressed by Polycomb in ESCs are kept in a poised state through their 582 
association with an unusual form of RNAPII characterized by the S5p modification 583 
(Brookes et al, 2012; Ma et al, 2016; Stock et al, 2007; Tee et al, 2014). This 584 
promoter state is thought to play an important role in the regulation of cell plasticity, 585 
conferring pluripotent stem cells with the ability to rapidly activate specific subgroups 586 
of genes in response to developmental stimuli (Di Croce & Helin, 2013). However, 587 
how the interplay between Polycomb and poised RNAPII evolves upon differentiation 588 
has remained unexplored. Here, we optimized an in vitro differentiation approach to 589 
obtain functional dopaminergic neurons at different stages of maturation, and 590 
produced a comprehensive collection of datasets that provides an in depth profile of 591 
the transcriptional and promoter state dynamics during differentiation. We observe 592 
that promoter state transitions during differentiation are instructed by a tight interplay 593 
between RNAPII poising and Polycomb repression. We show for the first time that 594 
poising of genes by RNAPII-S5p occurs at intermediate and terminal stages of 595 
differentiation and that it associates with increased potential for reactivation upon loss 596 
of Polycomb repression. 597 
 598 
We show de novo acquisition of PRC marks at many promoters during differentiation, 599 
which coincide with downregulation of gene expression. Notably, we identify a 600 
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subgroup of genes that maintain the poised PRC/S5p conformation throughout all 601 
stages of differentiation studied, including many important transcription factors 602 
important for specification of non-neuronal lineages. We directly demonstrate the 603 
simultaneous co-association of H3K27me3 and RNAPII-S5p in differentiated neurons 604 
using sequential-ChIP, both at genes that acquire de novo PRC and that maintain the 605 
PRC/S5p state. 606 
 607 
We observe that the genes that maintain PRC/S5p throughout differentiation have a 608 
specific chromatin structure characterized by high CpG content, broad distributions of 609 
RNAPII-S5p and H3K27me3, and overlap with large hypomethylated regions or 610 
DMVs. This cohort of genes is enriched for developmental factors with key roles in 611 
non-neuronal lineages, such as heart, bone or epithelium. Differentiated cells can be 612 
reprogrammed and their identities altered in a process called trans-differentiation 613 
(Ladewig et al, 2013). To explore the implication of maintaining genes that encode 614 
for lineage-commitment TFs in a poised Polycomb-repressed configuration 615 
throughout differentiation, we considered whether they are candidate mediators of 616 
trans-differentiation. We discovered that the TFs that maintain the PRC/S5p promoter 617 
state during differentiation are important candidate drivers of trans-differentiation 618 
conversions. Future studies in other terminally differentiated cell types will help 619 
understand whether the poised chromatin state is an inherent state of repression for 620 
these important transcription factors, or alternatively whether distinct sets of poised 621 
PRC/S5p genes are specifically chosen in each specific cell type to restrict the 622 
potential to selectively reprogramming into another cell type, either during the normal 623 
physiology of a tissue or in disease.  624 
 625 
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 626 
In conclusion, our study identifies key roles of Polycomb repression and RNAPII-S5p 627 
poising in modulating the dynamic changes in gene expression that occur during ESC 628 
terminal differentiation into dopaminergic neurons, and provides comprehensive maps 629 
of gene expression and promoter states of repression which are a valuable resource for 630 
regenerative and developmental biology. Studying gene regulation in terminally 631 
differentiated neurons with a dopaminergic phenotype is of particular interest for 632 
understanding the biology behind Parkinson’s disease and for the generation of cells 633 
for replacement therapy as possible treatment. 634 
 635 
Materials and Methods 636 
Cell culture and differentiation 637 
Cells were grown at 37°C in a 5% (v/v) CO2 incubator. Mouse embryonic stem cells 638 
(ESC-46C; ES cell line E14tg2a that expresses GFP under Sox1 control; (Ying et al, 639 
2003), kindly provided by Domingos Henrique, were grown in GMEM medium 640 
(Invitrogen, Cat 21710025), supplemented with 10% (v/v) Fetal Calf Serum (FCS; 641 
BioScience LifeSciences, Cat 7.01 batch number 110006), 2000U/ml LIF (Millipore, 642 
Cat ESG1107), 0.1 mM -mercaptoethanol (Invitrogen, Cat 31350-010), 2 mM L-643 
glutamine (Invitrogen, Cat 25030-024), 1 mM sodium pyruvate (Invitrogen, Cat 644 
11360039), 1% penicillin-streptomycin (Invitrogen, Cat 15140122), 1% MEM Non-645 
Essential Amino Acids (Invitrogen, Cat 11140035) on gelatin-coated (0.1% v/v) 646 
Nunc T25 flasks. The medium was changed every day and cells were split every other 647 
day. Before sample collection for ChIP-seq and mRNA-seq, ESCs were plated on 648 
gelatin-coated (0.1% v/v) Nunc 10 cm dishes in serum-free ESGRO Complete Clonal 649 
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Grade Medium (Millipore, Cat SF001-B) to which was added 1000U/ml LIF. Cells 650 
were grown for 48h, with a medium change at 24h. ESC batches were tested for 651 
mycoplasma infection. 652 
 653 
Early neuronal differentiation was optimized based on the method described in 654 
(Abranches et al, 2009). ESCs were plated with high density (1.5x105 cells/cm2) in 655 
serum-free ESGRO Complete Clonal Grade Medium (Millipore, Cat SF001-B) to 656 
which 1000U/ml LIF was added. After 24 hours, ESCs were washed 3 times with 657 
PBS without magnesium and calcium, incubated in PBS for 3 min at room 658 
temperature and then dissociated by incubating in 0.05% (v/v) Trypsin (Gibco, Cat 659 
25300-054) for 2 min at 37°C. ESCs were plated onto 0.1% (v/v) gelatin-coated 10 660 
cm dishes (Nunc) at 1.6x106 cells/dish in RHB-A (Takara-Clontech, Cat Y40001), 661 
changing media every day.  662 
Mouse EpiSCs were established from ESC-46C after growth (4 weeks) in N2B27 663 
basal medium containing 20 ng/ml of Activin (R&D, Cat 338-AC-050) and 12 ng/ml 664 
FGF2 (Peprotech, Cat 100-18B). The composition of the N2B27 basal medium was: 665 
½ of DMEM/F12 (Invitrogen, Cat 21331-020), ½ of Neurobasal Medium 666 
(Invitrogen, Cat 21103-049), 0.5x N2 (Invitrogen, Cat 17502-048), 0.5x B27 667 
(Invitrogen, Cat 12587-010), 0.05 M -mercaptoethanol (Invitrogen, Cat 31350-668 
010) and 2 mM L-glutamine (Invitrogen, Cat 25030-024). EpiSC were grown on 669 
Nunc plates coated with FCS (BioScience LifeSciences, Cat 7.01 batch number 670 
110006). Culture medium was changed every day and cells were split every other day, 671 
by washing 3 times with PBS without magnesium and calcium, incubating in PBS for 672 
3 min at room temperature, gently scraping them from the plate pipetting up and 673 
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down 3 times, before transferring to a new FCS-coated plate. The mouse EpiSC-674 
Pitx3-GFP line was previously established in the Li laboratory (Jaeger et al, 2011), 675 
from ESC-Pitx3-GFP (Zhao et al, 2004). Frozen cell batches were tested for 676 
mycoplasma infection. 677 
EpiSCs were differentiated into day 16 and 30 neurons with midbrain properties using 678 
a protocol optimized based on the method developed in (Jaeger et al, 2011). 679 
The day before starting the differentiation protocol (day ‘-1’), growing EpiSCs were 680 
plated on Nunc plates coated with 15 g/ml human plasma fibronectin (Millipore, 681 
Cat FC010) and cultured in N2B27 basal medium containing Activin and FGF2, to 682 
reach 70-80% confluency after 24h. Differentiation was started by rinsing cells twice 683 
with PBS, and culturing in N2B27 basal medium plus 1M PD 0325901 (Axon, Cat 684 
1408) for 2 days. Medium was refreshed every day. On day 2, cells were washed with 685 
PBS, scraped, replated on Nunc 10 cm dishes coated with 15 g/ml human plasma 686 
fibronectin (Millipore, Cat FC010) and cultured in N2B27 basal medium for 3 days. 687 
At this stage, medium was refreshed every day by removing ½ volume and adding ½ 688 
volume of freshly prepared medium. 689 
After 72h, the medium was replaced with N2B27 basal medium plus 100 ng/ml FGF8 690 
(Peprotech, Cat 100-25-25) and 200 ng/ml Shh (R&D, Cat 464-sh-025). Medium 691 
was refreshed every day by removing ½ volume and adding ½ volume of freshly 692 
prepared medium. 693 
After 96h, cells were washed with PBS, and the medium replaced with N2B27 basal 694 
medium plus 10 ng/ml BDNF (R&D, Cat 450-02-10), 10 ng/ml GDNF (R&D, Cat 695 
450-10-10) and 200 M L-ascorbic acid (Sigma, Cat A4544). Medium was refreshed 696 
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every day by removing ½ volume and adding ½ volume of freshly prepared medium 697 
until days 16 and 30. 698 
EZH1 and EZH2 enzymatic inhibition on ESCs, day 3 and day 30 differentiated cells 699 
was carried out adding 1 or 3 M of UNC 1999 (Konze et al, 2013) Sigma, Cat 700 
SML0778) dissolved in DMSO directly to the medium. Cells treated with UNC 1999 701 
and control cells treated with DMSO were incubated for 24h with drug/vehicle before 702 
RNA collection. 703 
 704 
mRNA expression 705 
Total RNA was prepared from cells using TRIzol (Invitrogen, Cat 15596-018) 706 
extraction following the manufacturer's instructions. Total RNA was treated with 707 
TURBO DNase I (Ambion, Cat AM1907) according to the manufacturer’s 708 
instruction. Extracted RNA (1 μg) was reverse transcribed with 50 ng random primers 709 
and 10 U reverse transcriptase (Superscript II kit, Invitrogen, Cat 11904-018) in a 20 710 
μl reaction. The synthesized cDNA was diluted 1:10, and 2.5 μl used for qRT-PCR. 711 
Results were normalized to Actb. mRNA libraries were made using TruSeq RNA 712 
Sample Preparation Kits v2 setA (Illumina, Cat RS-122-2001) and sequenced 713 
paired-end using Illumina Sequencing Technology by an Illumina HiSeq2000 714 
following the manufacturer's instructions. The primers used are reported in the table 715 
below. 716 
 717 
RNA Primers  
β-actin Fw TCTTTGCAGCTCCTTCGTTG Rev ACGATGGAGGGGAATACAGC 
Nanog Fw ATGAAGTGCAAGCGGTGGCAGAAA Rev CCTGGTGGAGTCACAGAGTAGTTC 
Oct4 Fw CTGAGGGCCAGGCAGGAGCACGAG 
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Rev CTGTAGGGAGGGCTTCGGGCACTT 
Fgf5 Fw CTTCTGCCTCCTCACCAGTC Rev CACTCTCGGCCTGTCTTTTC 
Blbp Fw GGGTAAGACCCGAGTTCCTC Rev ATCACCACTTTGCCACCTTC 
Hes5 Fw AAGTACCGTGGCGGTGGAGAT Rev CGCTGGAAGTGGTAAAGCAGC 
Mash1 Fw TGGAGACGCTGCGCTCGGC Rev CGTTGCTTCAATGGAGGCAAATG 
Sox2 Fw CATGTGAGGGCTGGACTGCG Rev GCTGTCGTTTCGCTGCGG 
Skor1 Fw GCTAAGTGCATCAAGTGCGG Rev CACGAGTTAAAGTTGGCGGC 
Gata4 Fw GAGGCTCAGCCGCAGTTGCAG Rev CGGCTAAAGAAGCCTAGTCCTTGCTT 
HoxA7 Fw AAGCCAGTTTCCGCATCTACC Rev GTAGCGGTTGAAATGGAATTCC 
Pitx1 Fw CAGATCAGCGTCGGACGATT Rev CACCACCACCGCACGAC 
Mesp1 Fw CGCAGTCGCTCGGTCC Rev GGATGCTGTTTCTGCGTACAG 
Pou2f3 Fw GATCCTCTTTAGAGCCCCACCTG Rev TCAGTGGGCTCATCATTCCCTC 
Pkp1 Fw TACGAATGCTTCCAGGACCA Rev ACTTCTGCCGTTTGACGGT 
She Fw CCGTAAGAACTCCCGGGTCA Rev TCCCATTCTTCTCCTGCGTG 
Fam150b Fw CGCTGCTGAGGTTGCTAGTT Rev CTCTGCTCCTCTTGGTCTGC 
Fgf20 Fw GAGGCAGCAAGAAGTGCGA Rev ATTTCAGTCATCCTGTCCGGC 
Chrdl2 Fw GAAAAGATATATACCCCCGGCCA Rev TCAGAGCAGGTACAGCGCAC 
Tal1 Fw GCACCTAGTCCTGCTCAACG Rev GGCCCTTTAAGTCCCTCGC 
 718 
 719 
Incorporation of BrdU in replicating cells 720 
To measure replication index, cells were grown in their normal medium in the 721 
presence of 50 M BrdU (Sigma, Cat 59-14-3) for 24h. Cells were fixed (10 min) 722 
with 4% freshly-depolymerized paraformaldehyde in 125 mM HEPES (pH 7.8). After 723 
washing (2x) in PBS, cells were permeabilized (20 min) with 0.2% Triton X-100 in 724 
PBS and blocked (30 min) with blocking solution (0.5% BSA, 0.2% fish skin gelatin 725 
  
31 
in PBS). Cells were incubated in blocking solution (1h, humid dark chamber) to 726 
which were added 0.5 U/L DNaseI (Sigma, Cat D4263), 3 mM MgCl2 and anti-727 
BrdU antibody (1:150; raised in mouse which detected BrDNA after in vivo 728 
incorporation of BrdU into replicating DNA; Caltag Laboratories, Cat MD5110). 729 
Cells were washed (3x, 3 min each) with blocking solution and incubated (40-60 min) 730 
with blocking solution containing the secondary antibody anti-Mouse IgG conjugated 731 
with Alexa Fluor 555 (1:1000; raised in donkey; Invitrogen, Cat A31570), in a 732 
humid dark chamber. Cells were rinsed (2x) with blocking solution and (2x) with 733 
PBS. Cells were stained (5 min) in 0.1 mg/ml DAPI in PBS, washed (1x) with PBS 734 
and mounted using Dako Fluorescence Mounting Medium (Dako Agilent 735 
Technologies, Cat S3023). 736 
 737 
Protein immunofluorescence  738 
Cells were fixed (10 min) with 4% freshly depolymerized paraformaldehyde in 125 739 
mM HEPES, washed twice with PBS and permeabilized (3x, 5 min each) with 0.3% 740 
Triton X-100 in PBS (PBST), by gently rocking. Cells were blocked (30 min) with 741 
3% donkey serum in PBST and then incubated (at 4C, overnight), with primary 742 
antibody in PBST+3% donkey serum. Primary antibodies used were: mouse Tuj1 743 
(1:500; Sigma, Cat T8660); mouse anti-OCT4 (1:50; BD Biosciences, Cat 611202); 744 
sheep anti-TH (1:500; Pel-Freez, Rogers-Arkansas, Cat P60101-0). After washing 745 
(3x, 10 min each) with PBST, cells were incubated (1h, in a humid dark chamber) 746 
with secondary antibodies Alexa Fluor 555 anti-mouse IgG (1:1000; raised in donkey; 747 
Invitrogen, Cat A31570) or Alexa Fluor 555 anti-sheep IgG (1:500; raised in 748 
donkey; Invitrogen, Cat A21436) in PBST+3% donkey serum. After three washes in 749 
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PBS (10 min each), cells were incubated (5 min) in 0.1 mg/ml DAPI in PBS, washed 750 
with PBS (3x, 10 min each), before mounting in Dako Fluorescence Mounting 751 
Medium (Dako, Cat S3023). 752 
For double immunostaining of LMX1A and FOXA2, cells were permeabilized (3x, 5 753 
min each) with 0.3% Triton X-100 in PBS (PBST), by gently rocking. Cells were 754 
blocked (30 min) with 3% donkey serum in PBST and then incubated (at 4C, 755 
overnight), with anti-FOXA2 antibodies (1:200; raised in goat; Santa Cruz, Cat sc-756 
6554) in PBST+3% donkey serum. After washing (3x, 10 min each) with PBST, cells 757 
were incubated (1h, in a humid dark chamber) with secondary antibodies Alexa Fluor 758 
555 anti-goat IgG (1:500; raised in donkey; Invitrogen, Cat A21432) in PBST+3% 759 
donkey serum. Cells were washed (3x, 10 min each) with PBST+3% donkey serum 760 
cells, stored (5h) in 3% donkey serum in PBST, before incubation (at 4C, overnight), 761 
with guinea pig LMX1A (1:500; clone GP6; custom made antibody generated in the 762 
Li laboratory) in PBST+3% donkey serum. After washing (3x, 10 min each) with 763 
PBST, cells were incubated (1h, in a humid dark chamber) with secondary antibodies 764 
anti-guinea pig IgG conjugated with Alexa Fluor 488 (1:500; raised in goat; 765 
Invitrogen, Cat A11073) in PBST+3% donkey serum.  766 
After three washes in PBS (10 min each), cells were incubated (5 min) in 0.1 mg/ml 767 
DAPI in PBS, washed with PBS (3x, 10 min each), before mounting in Dako 768 
Fluorescence Mounting Medium (Dako, Cat S3023). 769 
For triple immunostaining of dopaminergic, GABAergic and glutamatergic markers 770 
(Fig EV3G), fixed cells were washed (3x) in PBST (PBS containing 0.1% Triton X-771 
100) and incubated 2h in a blocking solution that contained 5% donkey serum and 3% 772 
BSA in PBST. Primary antibodies used were: sheep anti-TH (1:500, Pel-Freez, 773 
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Rogers-Arkansas, Cat P60101-0), mouse anti-VGluT2 (vesicular glutamate 774 
transporter 2, 1:1000, Millipore, Cat MAB5504), and rabbit anti-GABA (gamma-775 
aminobutyric acid, 1:1000, Sigma, Cat A2052). The primary antibodies were diluted 776 
in blocking solution and incubated overnight at 4°C. The next day, cells were washed 777 
(3x) with PBST and bathed (1h) in secondary antibodies Alexa Fluor 488 anti-sheep 778 
IgG (1:200, raised in donkey, Molecular Probes, Cat A-11015), Alexa Fluor 555 779 
anti-rabbit IgG (1:200, raised in donkey, Molecular Probes, Cat A-31572), and 780 
Alexa Fluor 647 anti-mouse IgG (1:200, raised in donkey, Molecular Probes, Cat A-781 
31571) diluted in blocking solution, and after three washes in PBS, mounted with 782 
Dako Fluorescence Mounting Medium (Dako, Cat S3023). 783 
 784 
Microscopy 785 
Single immunofluorescence images (Fig 1C and D) were collected sequentially on a 786 
confocal laser-scanning microscope (Leica TCS SP8 STED; HC PLAPOCS2 787 
20x/0.75 IMM objective), equipped with a 405 diode and a WLL (Supercontinuum 788 
visible) laser, and pinhole equivalent to 1 Airy disk. For comparison of the different 789 
staining during neuronal differentiation, images were collected on the same day using 790 
the same settings, and without saturation of the intensity signal.  791 
Double and triple immunofluorescence images (Fig EV1C and 3G) were acquired on 792 
a confocal laser-scanning microscope (Leica TCS SP5; HCX PL APO CS 40.0x1.25 793 
OIL objective) equipped with a 405 nm diode, and Argon (488 nm), HeNe (543 nm) 794 
and HeNe (633 nm) lasers. 795 
 796 
Electrophysiology  797 
  
34 
Coverslips of mature neuronal cultures were placed onto a recording chamber and 798 
viewed using an Olympus BX51WI microscope with a 40x water immersion lens and 799 
DIC (differential interference contrast) optics. Cells were bathed at room temperature 800 
in a solution containing (in mM): 140 NaCl, 3.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 1 801 
MgCl2, 10 Glucose, and 10 HEPES (pH 7.4). For whole-cell electrophysiological 802 
recordings, low resistance recording pipettes (8-14 M) were pulled from capillary 803 
glass (Harvard Apparatus Ltd.) and coated with ski wax (Toko) to reduce pipette 804 
capacitance. Recording pipettes were filled with a solution containing: 140 mM K-805 
gluconate, 5 mM NaCl, 2 mM ATP, 0.5 mM GTP, 0.1 mM CaCl2, 1 mM MgCl2, 1 806 
mM ethylene glycol-bis (b-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), and 807 
10 mM HEPES (pH 7.4). For recordings of mIPSCs, a high-chloride solution was 808 
used: 135 mM CsCl, 4 mM NaCl, 2 mM ATP, 0.3 mM GTP, 0.5 mM MgCl2, 2 mM 809 
EGTA, and 10 mM HEPES (pH 7.4). Pitx3-GFP positive neurons were identified and 810 
targeted using fluorescence via a GFP selective filter (X-Cite series 120, EXFO). For 811 
analysis of synaptic physiology, cells were held in voltage-clamp mode at -70 mV and 812 
events were detected over 3 min of recording. The first 30 s of recording were used 813 
for analysis of action potentials (i.e., frequency and CV-ISI). Cells were excluded 814 
from analysis if they exhibited a holding current greater than -150 pA, a series 815 
resistance greater than 30 M, or if the holding current did not remain stable over the 816 
course of recording. Antagonists were dissolved in the extracellular solution and 817 
applied to the cultures via bath perfusion at 30 - 33°C. The sodium channel blocker 818 
tetrodotoxin citrate (TTX) was used at 1 µM (Tocris Bioscience, Cat 1069). In order 819 
to block glutamatergic synaptic activity, 2,3-dioxo-6-nitro-1,2,3,4- 820 
tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX; Sigma, Cat N171), an AMPA 821 
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receptor antagonist, was used at 5 µM, while Picrotoxin (100 µM, Sigma, Cat 822 
P1675), a GABAA receptor antagonist, was used to identify GABAergic synaptic 823 
events. Data were acquired using an Axon Multiclamp 700B amplifier and a Digidata 824 
1440a acquisition system, with pClamp 10 software (Molecular Devices). Data 825 
analysis was carried out using Clampfit 10.2 software (Axon Instruments), OriginPro 826 
8.1 (OriginLab Corporation), Spike2v5 software (Cambridge Electronic Design), and 827 
MiniAnalysis software v6.0.7 (Synaptosoft). Data are presented as either percentage 828 
of cells or the mean ± standard error of the mean (SEM). Statistical analyses were 829 
performed using either chi-squared test for trend or a one-way ANOVA (Kruskal-830 
Wallis; GraphPad Prism, GraphPad Software, San Diego, CA). Significance was 831 
noted when p < 0.05. 832 
 833 
Chromatin Immunoprecipitation (ChIP), ChIP-seq and re-ChIP 834 
The chromatin from ESCs or differentiated cultures was prepared by crosslinking in 835 
1% formaldehyde for 10 min as previously described (Brookes et al, 2012; Stock et al, 836 
2007). Arbitrary ‘chromatin concentration’ was obtained by measuring absorbance 837 
(280 nm) of alkaline-lysed chromatin, and using the conversion 50 mg/ml for 1 838 
absorbance unit. For mouse anti-RNAPII-S5p (clone CTD4H8, BioLegend, Cat 839 
904001), mouse anti-digoxigenin (Jackson Immunoresearch, Cat 200-002-156) and 840 
rat anti-RNAPII-S7p (4E12; (Chapman et al, 2007); kindly provided by Dirk Eick) 841 
antibodies, protein-G-magnetic beads (Active Motif, Cat 53014) were incubated 842 
with rabbit anti-mouse (IgG+IgM) bridging antibodies (Jackson Immunoresearch, 843 
Cat 315-005-048; 10 μg per 50 μl beads) for 1h at 4°C and washed with sonication 844 
buffer. For rabbit anti-H3K27me3 (Millipore, Cat 07-449) antibodies, magnetic 845 
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beads were just washed with sonication buffer. Fixed (700 μg) chromatin was 846 
immunoprecipitated (4°C, overnight) with the specific antibody and 50 μl beads 847 
(with/without bridging antibody), according to (Stock et al, 2007) and (Brookes et al, 848 
2012). After immunoprecipitation using IgG antibodies, beads were washed as 849 
described previously (Stock et al, 2007). Immune complexes were eluted from beads 850 
(65°C, 5 min then room temperature, 15 min) with 50 mM Tris-HCl pH 8.0, 1 mM 851 
EDTA and 1% SDS. Elution was repeated once and eluates pooled. Reverse cross-852 
linking was carried out (8h, 65°C) after addition of NaCl and RNase A. EDTA was 853 
then increased to 5 mM and samples were incubated (50°C, 2h) with 200 μg/ml 854 
proteinase K (Roche, Cat 3115836001). DNA was recovered by phenol-chloroform 855 
extraction and ethanol precipitation. The final DNA concentration was determined by 856 
Quant-iT PicoGreen dsDNA Assay Kit fluorimetry (Thermo Fisher Scientific, Cat 857 
P7589). The quality of immunoprecipitated DNA used for high-throughput 858 
sequencing was confirmed prior to library preparation by quantitative real-time PCR 859 
(qPCR) analyses of Active, PRC/S5p and Inactive genes with previously 860 
characterized chromatin states (Brookes et al, 2012); these quality control tests are not 861 
shown. Samples were diluted to the same concentration (0.2 ng/μl). The same amount 862 
of immunoprecipitated and input DNA (0.5 ng) were analyzed by qPCR using primers 863 
with the previously published sequences (Brookes et al, 2012). Amplifications (40 864 
cycles) were performed using SensiMix No-ROX Kit (Bioline, Cat QT650-05) with 865 
DNA Engine Opticon 1/2 Real Time PCR system (BioRad, Hemel Hempstead, 866 
Hertfordshire, UK).  867 
ChIP-seq libraries were prepared from 10 ng DNA (quantified by PicoGreen and 868 
Qubit) using the Next ChIP-Seq Library Prep Master Mix Set for Illumina (NEB, 869 
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Cat E6240) following the NEB protocol, with some modifications. The intermediate 870 
products from the different steps of the NEB protocol were purified using MinElute 871 
PCR purification kit (Qiagen, Cat 28004). Adaptors, PCR amplification primers and 872 
indexing primers were from the Multiplexing Sample Preparation Oligonucleotide Kit 873 
(Illumina, Cat PE-400-1001). Samples were PCR amplified prior to size selection on 874 
an agarose gel (250-600 bp including adapters). The size range was selected due to 875 
the broad distribution of RNAPII and H3K27me3 at promoters, where there is 876 
evidence that protection of DNA may occur (Ferrai et al, 2007; Ferrai et al, 2010). 877 
After purification by QIAquick Gel Extraction kit (Qiagen, Cat 28704), libraries 878 
were quantified by Qubit (Invitrogen) and by qPCR using KAPA Library 879 
Quantification Universal Kit (KapaBiosystems, Cat KK4824). Library size was 880 
assessed before high-throughput sequencing by Bioanalyzer (Agilent) using the High 881 
Sensitivity DNA analysis kit (Agilent, Cat 5067-4626). Fragment sizes were within 882 
the selected size distribution. ChIP-seq libraries were sequenced single-end using 883 
Illumina Sequencing Technology using an Illumina HiSeq2000, according to the 884 
manufacturer’s instructions.  885 
Re-ChIP experiments were performed as previously described (Brookes et al, 2012). 886 
The first ChIP was performed as described above with the exception that after the 887 
final wash in TE buffer, immune complexes were eluted from the beads twice (65°C, 888 
5 min, and room temperature, 15 min) using elution buffer (50 mM Tris pH 8.0, 1 889 
mM EDTA and 1% SDS). ‘Re-ChIP dilution’ buffer (55 mM HEPES pH 7.9, 154 890 
mM NaCl, 1.0 mM EDTA, 1.1% Triton X100, 0.11% Na-deoxycholate) was added to 891 
dilute the eluate 10-fold to reach a final SDS concentration of 0.1%. The second 892 
round of immunoprecipitation was set up following the standard ChIP protocol. 893 
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Enrichment relative to the input chromatin material was obtained using qPCR (see 894 
above) using the same amount of DNA in each PCR. To test carry-over from the first 895 
immunoprecipitation, an unrelated antibody anti-digoxigenin (raised in mouse; 896 
Jackson Immunoresearch, Cat 200-002-156) was used in the second round of 897 
immunoprecipitation. As a positive control, RNAPII-S5p ChIP was repeated in the 898 
second immunoprecipitation. The primers used for Re-ChIP are reported in the table 899 
shown below. 900 
 901 
Re-ChIP Primers 
β-actin Fw GCAGGCCTAGTAACCGAGACA Rev AGTTTTGGCGATGGGTGCT 
Pitx1 Fw CAGATCAGCGTCGGACGATT Rev CACCACCACCGCACGAC 
Gata4 Fw TTCCCAGAAAACCGGCGCGA Rev CCCTTAGGCCAGTCAGCGCA 
Skap2 Fw TCCGGCTGTCCAGGGAGGAT Rev CACCCTATGCGGACGGTGGG 
Ajuba Fw GCCCTGCCTCTGCCTCTGTC Rev CGAGTGACGGCTCTCCTGGC 
Myf5 Fw GGAGATCCGTGCGTTAAGAATCC Rev CGGTAGCAAGACATTAAAGTTCCGTA 
 902 
Bioinformatics 903 
Read mapping and visualisation  904 
Sequenced single-end (50-51 bp) reads originating from ChIP-seq libraries were 905 
aligned to the Mouse reference genome mm10 (Dec. 2011, GRCm38/mm10) using 906 
Bowtie2 v2.0.5 (Langmead & Salzberg, 2012). The reference genome was indexed 907 
and the alignments were performed with default parameters. Replicated reads (i.e. 908 
identical reads, aligned to the same genomic location), occurring more often than the 909 
95th percentile of the frequency distribution of each dataset, were removed. When 910
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reads originated from multiple runs (technical replicates of sequencing), datasets were 911 
merged after mapping and removal of replicated reads. 912 
Sequenced paired-end (2x100bp) reads from mRNA-seq libraries were aligned for 913 
visualisation using TopHat v2.0.8 (Trapnell et al, 2009). The gene references 914 
provided to TopHat were the gtf annotation from UCSC Known Genes (mm10, 915 
version 6) and the associated isoform-gene relationship information from the Known 916 
Isoforms table (UCSC). Tables were downloaded from the UCSC Table browser 917 
(http://genome.ucsc.edu/cgi-bin/hgTables). UCSC Genome Browser 918 
(http://genome.ucsc.edu) was used for Fig 4B, 6E, Fig EV2A and Fig EV3G using 919 
default view settings, except: Windowing function – Mean, Smoothing Window - 2 920 
pixels and inclusion of zero on y-axis. Number of mapped reads for the datasets 921 
produced for this study is shown in the table below. 922 
 923 
ChIP-seq dataset Cell type Read type Mapped reads (millions) 
RNAPII-S5p 46C- ESC 1x50bp 46 
RNAPII-S5p 46C- day1 1x50bp 82 
RNAPII-S5p 46C- day3 1x50bp 75 
RNAPII-S5p 46C- day16 1x50bp 95 
RNAPII-S5p 46C- day30 1x50bp 58 
RNAPII-S7p 46C- ESC 1x50bp 68 
RNAPII-S7p 46C- day1 1x50bp 65 
RNAPII-S7p 46C- day3 1x50bp 87 
RNAPII-S7p 46C- day16 1x50bp 50 
RNAPII-S7p 46C- day30 1x50bp 81 
H3K27me3 46C- ESC 1x50bp 40 
H3K27me3 46C- day1 1x50bp 42 
H3K27me3 46C- day3 1x50bp 62 
H3K27me3 46C- day16 1x50bp 48 
H3K27me3 46C- day30 1x50bp 32 
Control (Dig) 46C- ESC 1x51bp 67 
Control (Dig) 46C- day16 1x50bp 21 
polyA mRNA-seq 
dataset 
Cell type Read type Mapped reads (millions) 
  
40 
ESC 46C- ESC 2x100bp 48 
day1 46C- day1 2x100bp 46 
day3 46C- day3 2x100bp 47 
day16 46C- day16 2x100bp 40 
day30 46C- day30 2x100bp 51 
 924 
 925 
Non-redundant gene list selection  926 
To investigate the most representative isoform for each gene in each time point, we 927 
followed the same strategy as in (Brookes et al, 2012), applied to mouse genome 928 
assembly mm10. To define isoforms and link them to gene clusters, we used UCSC 929 
Known Gene table (mm10, version 6) and the associated UCSC Known Isoforms 930 
table. Genes belonging to the mitochondrial genome (chrM) or ‘random 931 
chromosomes’ (chr_random) were discarded. We also discarded clusters not linked to 932 
any RefSeq annotation (from the associated UCSC kgXref table). After filtering, we 933 
obtained a dataset of 23177 gene clusters, associated to one or more RefSeq genes. 934 
Around half of the gene clusters, 11331, had a single isoform. When more than one 935 
isoform (UCSC Known Gene identifier) was present in a cluster, we selected one 936 
isoform per time point using the following criteria: 937 
1. We selected the gene isoform with the highest amount of reads for RNAPII-938 
S5p in a 2kb window centred on the TSS (Transcription Start Site; in 15.7-939 
17.1% of gene clusters the isoform was selected at this step);  940 
2. If ambiguity was still present, we selected the isoform with the highest 941 
RNAPII-S2p in a 4kb window centred on the TES (Transcription End Site; in 942 
13.3-13.9% of gene clusters the isoform was selected at this step);  943 
3. If ambiguity was still present, we selected the canonical isoform annotated in 944 
the associated UCSC mm10 known Canonical table (the gene with the highest 945 
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number of coding bases; in 20.5-21.3% of gene clusters the isoform was 946 
selected at this step); and, 947 
4. If ambiguity was still present, one isoform was selected randomly (in 0.1-0.2% 948 
of gene clusters the isoform was selected at this step).  949 
 950 
Promoter classification  951 
To define genome-wide enriched regions for RNAPII-S5p, S7p and H3K27me3, for 952 
each time point, we used Bayesian Change-point Model (BCP) peak-finder (Xing et 953 
al, 2012). BCP performs well in detecting enriched regions for broad chromatin 954 
features such as (broad) histone marks or RNAPII (Harmanci et al, 2014; Thomas et 955 
al, 2016). BCP was run in Histone Mark (HM) mode using as control dataset: (a) 956 
control (digoxigenin) ChIP-seq from ESCs, for ESC, day 1 and day 3 datasets or (b) 957 
control (digoxigenin) ChIP-seq from day 16 neurons, for day 16 and 30 datasets. 958 
Gene promoters were considered positive for RNAPII-S5p, S7p or H3K27me3 when: 959 
(a) the 2 kb-windows centred on the TSS overlapped with a region enriched for the 960 
mark, and (b) the amount of reads in the TSS window was above a threshold. The 961 
threshold was defined as the 5th percentile of the distribution of reads in the TSS 962 
window of positive genes (5% tail cut).  963 
To remove overlapping genes, we excluded genes whose (positive) TSS window 964 
overlapped positive windows for the same mark of other genes for more than 10% 965 
(200bp). Positive genes that were inside other positive genes for the same mark were 966 
also excluded (internal gene removed). Excluded genes are marked as NA in Dataset 967 
EV2. Genes classified as NA for at least one of the three marks used for the 968 
classification (RNAPII-S5p, S7p or H3K27me3) in one time point were excluded 969 
from further analyses. The genes that passed these filters (19352) were classified, in 970 
  
42 
each time point, according to the combination of RNAPII and H3K27me3 as 971 
belonging to one of eight different promoter states using the logics presented in main 972 
text (Fig 5A). The complete promoter classification is shown in Dataset EV2.  973 
 974 
mRNA-seq analyses 975 
To calculate expression estimates, mRNA-seq reads were mapped with STAR 976 
(Spliced Transcripts Alignment to a Reference, v2.4.2a; (Dobin et al, 2013) and 977 
processed with RSEM (RNA-Seq by Expectation-Maximization, v1.2.25; (Li & 978 
Dewey, 2011). The references provided to STAR and RSEM were the gtf annotation 979 
from UCSC Known Genes (mm10, version 6) and the associated isoform-gene 980 
relationship information from the Known Isoforms table (UCSC). Both tables were 981 
downloaded from the UCSC Table browser (http://genome.ucsc.edu/cgi-982 
bin/hgTables). Gene-level expression estimates in Transcript Per Million (TPM) were 983 
used for all the analyses and are reported in Dataset EV2.  984 
To select genes that peak in one specific time point (Fig 1E), the expression levels 985 
from genes in the non-redundant list were standardised across time points using z-986 
scores (calculated as the TPM value in each time point minus the mean value across 987 
the five time points, divided by the standard deviation). Then, genes whose 988 
standardised expression was higher than 1.75 in one time point were selected. Genes 989 
needed to be expressed (>1 TPM) in at least one time point to be included in the 990 
analysis.  991 
Statistical tests were performed using R and the name of the test is specified in main 992 
text. 993 
 994 
Gene Ontology Enrichment 995 
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Gene ontology (GO) enrichment analysis was performed using GO-Elite version 1.2.5 996 
(Gladstone Institutes; http://genmapp.org/go_elite). Pruned results (to decrease term 997 
redundancy) are reported. Default parameters were used as filters: z-score threshold 998 
more than 1.96, p-value less than 0.05, number of genes changed more than 2. Over-999 
representation analysis was performed with "permute p-value" option, 2000 1000 
permutations. Permute p-value is reported in figures. UCSC Known Gene IDs were 1001 
converted into the correspondent Ensembl Gene IDs (using the UCSC 1002 
KnownToEnsembl table, downloaded from the UCSC Table browser 1003 
http://genome.ucsc.edu/cgi-bin/hgTables) before performing the GO enrichment 1004 
analyses. The group of genes used as background for each analysis is specified in the 1005 
associated figure legend. The complete list of enriched pruned GO terms is shown in 1006 
Dataset EV1. 1007 
 1008 
Comparisons with published datasets 1009 
To compare PRC positive genes in this study with previously published work, the list 1010 
of genes whose promoter is classified as positive for H3K27me3 in ESC-46C was 1011 
overlapped with available resources as follows: 1012 
1. List of genes positive for H3K27me3 in (Young et al, 2011), defined using the 1013 
classification provided in Supplementary Table 2 of the corresponding paper. In 1014 
particular, genes classified as ‘Marked’, ‘Broad’, ‘Promoter’ or ’TSS’ in the ‘ES 1015 
H3K27me3’ column were considered. Genes were matched with our classification 1016 
using Ensembl Gene ID identifiers, converted from UCSC IDs as previously 1017 
described. 1018 
2. List of genes positive for H3K27me3 in (Lienert et al, 2011) or in (Brookes et al, 1019 
2012), were obtained from Table S2 (Brookes et al, 2012), i.e. the genes classified as 1020 
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‘1’ in columns ‘H3K27me3 (TSS) (Lienert et al., 2011)’ or ‘H3K27me3 (TSS) 1021 
(Mikkelsen et al., 2007)', respectively. Genes were matched with our classification 1022 
using Gene Symbols. Percentages were calculated as the number of genes positive in 1023 
both classifications divided for the number of ESC-46C H3K27me3 positive genes 1024 
present in the published lists. 1025 
To compare PRC/S5p genes in this study with bivalent genes, the list of genes whose 1026 
promoter is classified as positive for H3K27me3 and RNAPII-S5p in ESC-46C was 1027 
overlapped with list of bivalent genes (‘K4+K27’, ‘ESC’) in Supplementary Table 3 1028 
in (Mikkelsen et al, 2007). Genes were matched with our classification using Gene 1029 
Symbols. We find 69% of bivalent genes in Mikkelsen et al, 2007 are positive for 1030 
H3K27me3 and RNAPII-S5p in our ESC datasets.  1031 
 1032 
Up-regulated genes in published Polycomb knockout datasets  1033 
To explore the effect of PRC1/2 knockout in ESCs on the genes which are marked by 1034 
H3K27me3 in presence or absence of RNAPII-S5p, we mined published resources. 1035 
Expression values of wild type and Eed knockout ESCs (Cruz-Molina et al, 2017) 1036 
were obtained from GEO Gene Expression Omnibus repository (GSE89210). 1037 
Identifiers were then matched via EnsemblGene IDs. Fold change was calculated as 1038 
ratio between the average FPKM value in Eed knockout ESCs relative to the average 1039 
FPKM value in wild-type ESCs. Genes were classified as upregulated if the Fold 1040 
change was >2 and the expression in Eed knockout ESC was >1 FPKM. Genes 1041 
classified as PRC/S5p, PRC Only or Inactive that were expressed >1 FPKM in the 1042 
published datasets for wild type ESCs were excluded from the analysis, as these are 1043 
unlikely to have matched repressed promoter states. The percentage of genes 1044 
upregulated in each promoter state was calculated relative to the number of genes in 1045 
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that promoter state found in the published dataset.  1046 
Expression values of control cells and tamoxifen-induced conditional Ring1B 1047 
knockout in Ring1A-/- knockout cells measured by microarray (Endoh et al, 2008) 1048 
were obtained from GEO (GSM265042 and GSM265043) and analysed as in 1049 
(Brookes et al, 2012). Identifiers were matched via Gene Symbols. The percentage of 1050 
genes upregulated in each promoter state was calculated in relation to the number of 1051 
genes with the same promoter state that are present in the published datasets. 1052 
To explore the effect of PRC2 knockout in neurons on genes marked by H3K27me3 1053 
in the presence or absence of RNAPII-S5p, we mined a published list of upregulated 1054 
genes from ex vivo medium spiny neurons from 6 month old control and Ezh1-/-; 1055 
Ezh2fl/fl; Camk2a-cre knockout mice, measured by microarray (from the 1056 
Supplementary Table 3 in (von Schimmelmann et al, 2016). Genes in the published 1057 
list were matched with our day 30 list of promoter states using Gene Symbols. 1058 
Microarray probes matching to more than one Gene Symbol were not considered. In 1059 
the absence of the total list of detected genes, the percentage of genes upregulated in 1060 
each promoter state was calculated relative to the total number of genes in that group. 1061 
 1062 
Plot generation  1063 
Heatmaps in Fig 1E and 3B and Fig EV4B were produced using the CRAN package 1064 
pheatmap (Kolde, 2015) in R.  1065 
Bar plots, dot plots and boxplots were produced using Excel or R. For mRNA-seq, a 1066 
pseudo-count of 10–4 was added to TPM prior to logarithmic transformation and 1067 
plotting. In Fig 7D, a pseudo-count of 1 was added to peak size H3K27me3 prior to 1068 
logarithmic transformation and plotting.  1069 
To facilitate comparison between days, in Fig 3B, the number of reads mapping in 1070 
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2kb windows around the TSS (transformed in log scale) for each gene was divided by 1071 
the threshold of minimal number of reads in positive genes (5% Threshold, see 1072 
section on Promoter Classification). To help visualisation, these values were then 1073 
scaled to have the same maximum value, and the minimum and maximum values of 1074 
the colour scale were set to 1 and 99% of the distribution, respectively. 1075 
Average ChIP-seq profiles (Fig 7B and C) were generated as previously (Brookes et 1076 
al, 2012), by plotting the average coverage in non-overlapping windows of 10 bp, 1077 
across genomic windows centred on the TSS and the TES using custom scripts.  1078 
 1079 
Peak size, GC content and CpG coverage calculation 1080 
To calculate the breath of H3K27me3 windows covering each gene (Fig 7D), we 1081 
calculated the size of the BCP-detected enriched region that overlaps the 2kb window 1082 
centered on the TSS of each gene. If more than one peak was present, the longest was 1083 
selected. To calculate the overlap between TSS window or gene body (TSS to TES) 1084 
with CpG islands, we used the CpG island definition from the mm10 cpgIslandExt 1085 
table, downloaded from UCSC Table Browser. For each gene, we used the isoform 1086 
selected in day 30 neurons. The overlap was computed with IntersectBed, part of 1087 
Bedtools v2.17.0 (Quinlan & Hall, 2010). To calculate the proportion of TSS window 1088 
composed of G or C nucleotides, the sequence of the 2kb window centred on the TSS 1089 
used in day 30 was extracted using bedtools 2.17.0 getfast and analysed using a 1090 
custom script. Statistical tests were performed using R and the name of the test is 1091 
specified in the text. 1092 
 1093 
DNA hypomethylated region and DNA methylation valley definition   1094 
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Hypomethyated regions (HMRs) from mouse brain, Frontal Cortex (Lister et al, 1095 
2013); dataset name: MouseFrontCortexMale22Mo), were downloaded from 1096 
Methbase (Song et al, 2013); http://smithlabresearch.org/software/methbase), a 1097 
resource from the Smith laboratory, accessed through the UCSC Table Browser. 1098 
HMRs were downloaded as a bed file, already mapped to mm10. DNA methylation 1099 
valleys (DMVs) were defined starting from HMR using custom scripts for proximity 1100 
clustering and 5kb size cut-off, following the approach used in (Xie et al, 2013).  1101 
 1102 
 1103 
 1104 
Mogrify 1105 
In order to identify candidate TFs required to convert a given cell type into another 1106 
regardless of their original identity, we extracted the influence ranks provided by the 1107 
Mogrify algorithm (Rackham et al, 2016). These ranks are calculated for each TF for 1108 
a conversion between any of 173 cell types or 134 tissue types based on the TFs 1109 
estimated ability to regulate the differential expression of its immediate network 1110 
neighborhood. For any given cell type, we take the average rank of the TF over every 1111 
possible conversion, for instance, the TF Sox2 is often ranked highly for cell 1112 
conversions into human neurons and as such has an average rank of 34.86 (the 1113 
maximum possible rank is 303). The full list of genes and extracted average ranks for 1114 
the transitions investigated here can be found in Dataset EV3. 1115 
Each human gene was then matched with the mouse homolog using homology table 1116 
from Ensembl, release84 (downloaded through BioMart 1117 
http://www.ensembl.org/biomart/). Matching was performed on Gene Names. 1118 
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Enrichment or depletion in particular promoter states from day 30 neurons was tested 1119 
in R with hypergeometric test.  1120 
Promoter state enrichment in genes with high or low influence on trans-differentiation 1121 
(estimated with their rank) was tested using Gene Set Enrichment Analysis 1122 
(Subramanian et al, 2005), in “GSEAPreranked” mode. GSEA tests whether a ranked 1123 
list (here, the TFs involved in trans-differentiation) is enriched in certain Gene Sets 1124 
(here, different promoter states in day 30 or all days). In “GSEAPreranked” mode, 1125 
GSEA is run against a user-supplied, ranked list of genes (the list of TFs involved in 1126 
trans-differentiation, using the influence ranks calculated by Mogrify) and tests for 1127 
statistically significant enrichment at either end of the ranking. Enrichment was 1128 
considered significant at a false discovery rate less than 25%. 1129 
 1130 
Data availability 1131 
ChIP-seq and mRNA-seq data have been submitted to the GEO repository under 1132 
accession number GSE94364. 1133 
 List of Enriched Gene Ontology (GO) terms and associated genes: Dataset EV1. 1134 
 List of Promoter classification and expression for genes in each time point: Dataset 1135 
EV2. 1136 
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Figure Legends 1504 
 1505 
Figure 1. Model of differentiation from pluripotent stem cells to terminal 1506 
dopaminergic neurons. 1507 
A. Schematic representation of the differentiation system used and the temporal 1508 
expression dynamics of differentiation stage markers.  1509 
B. RNA levels of differentiation stage markers were measured by qRT-PCR. Relative 1510 
levels are normalized to Actb internal control and values are plotted relative to the 1511 
highest expressed time point. Mean and standard deviation (SD) are from three 1512 
biological replicates. 1513 
C. Indirect immunofluorescence confirms expression of stage-specific markers at the 1514 
single cell level. OCT4 is a marker of pluripotent ESCs. Tuj1 is an antibody that 1515 
detects neuronal marker TUBB3 at day 16 and day 30 neurons. The cycling activity of 1516 
ESCs, day 16 and day 30 neurons was assessed by BrdU incorporation (24h) into 1517 
replicating BrDNA. Nuclei are counterstained with DAPI. Bar, 100 μm.  1518 
D. Tyrosine hydroxylase (TH; in red) is a marker of dopaminergic neurons. It is not 1519 
expressed in ESCs, and detected weakly in day 16 and broadly in day 30 neurons. 1520 
E. Gene expression dynamics across the differentiation time line for genes whose 1521 
expression peaks in a single time point (z-score > 1.75; from mRNA-seq). 1522 
Representative enriched GO terms were calculated using as background all genes 1523 
expressed (>1 TPM) in at least one time point. n, number of genes per group. Permute 1524 
p-value (GO-Elite) is shown.  1525 
 1526 
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Figure 2. Whole-cell electrophysiological recordings from in vitro differentiated 1527 
dopaminergic neurons show maturation of action potential firing and synaptic 1528 
activity. 1529 
A. Differential Interference Contrast (DIC) and GFP images showing a glass 1530 
micropipette recording from a Pitx3-GFP+ cell and examples of action potential (AP) 1531 
measurements. Bar, 35 μm. Immature neurons were generally silent or fired only a 1532 
single AP; they progressively started firing multiple APs in response to a depolarizing 1533 
current pulse, evoked spontaneous APs generated in response to a constant 1534 
depolarizing current injection, or spontaneous pacemaker-like APs when they were 1535 
fully mature. 1536 
B. Graph shows progressive functional neuronal maturation towards spontaneous AP 1537 
firing from days 14-16 to day 30 based on the % of their AP firing categories (n=21, 1538 
25, 10, 30; Spontaneous firing; chi-squared test for trend=20.58, p-value<0.0001). 1539 
C. Two traces from different cells illustrating the presence (black, arrow) or absence 1540 
(gray) of a hyperpolarisation-activated inward current (Ih), evoked by a 1541 
hyperpolarizing voltage pulse of -120 mV. Graph shows mean and standard error of 1542 
the mean (SEM). Ih amplitude progressively increases across differentiation days 1543 
(n=22, 10, 12, 20; ANOVA=2.565, p-value=0.0483). 1544 
D. Example trace of spontaneous excitatory post-synaptic currents (sEPSCs) recorded 1545 
at -70 mV and application of 1 µM Tetrodotoxin (TTX), which revealed miniature 1546 
EPSCs (mEPSCs).  1547 
E. Spontaneous synaptic activity emerged at days 20-25. Graph shows percentage of 1548 
neurons with spontaneous synaptic activity across differentiation days (n=10, 19, 8, 5; 1549 
chi-squared test for trend=20.76, p-value<0.0001). Frequency, but not amplitude of 1550 
mEPSCs continues to increase once synaptic activity has emerged (n=7, 7, 10; 1551 
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Frequency ANOVA=6.555, p-value=0.0377; Amplitude ANOVA=0.04457, p-1552 
value=0.978). 1553 
 1554 
Figure 3. PRC occupancy at gene promoters is highly dynamic throughout all 1555 
stages of the neuronal differentiation. 1556 
A. Numbers of PRC+ promoters from ESC to day 30. In terminally differentiated 1557 
neurons, 2178 genes are marked by H3K27me3.  1558 
B. Dynamic changes in H3K27me3 presence at gene promoters. Vertical lines 1559 
represent each of the promoters marked by H3K27me3+ in at least one time point. 1560 
Throughout differentiation, 1408 genes are marked by H3K27me3 (PRC Maintained), 1561 
2699 lose H3K27me3 (PRC Lost), and 1565 gain H3K27me3 (PRC Acquired). Color 1562 
represents number of reads in transcription start site (TSS) window, scaled for 1563 
visualization. 1564 
C. Examples of enriched GO terms and gene examples among the groups of genes 1565 
classified as PRC Maintained, Lost and Acquired, using as background all genes. 1566 
 1567 
Figure 4. RNAPII-S5p overlaps with Polycomb at all stages of differentiation 1568 
A. Schematic summarizing the strategy used to define promoter states through 1569 
differentiation based on the interplay between PRC and RNAPII. 1570 
B. Examples of single-gene ChIP-seq profiles across differentiation. Eif2b2 and Brs3 1571 
are always Active and Inactive, respectively. Adcy5 and Pkp1 are PRC/S5p in ESC 1572 
and days 1/3, but become Active or PRC Only, respectively. Pitx1 maintains the 1573 
poised PRC/S5p conformation from ESCs until day 30 neurons. Ajuba is Active in 1574 
ESCs but acquires H3K27me3 at day 16 while becoming downregulated. 1575 
  
61 
C. Proportion of H3K27me3+ promoters (dark red) marked by RNAPII-S5p (purple) 1576 
throughout differentiation. The vast majority of H3K27me3+ promoters are bound by 1577 
RNAPII-S5p in all time points. 1578 
D. Proportion of H3K27me3+ and S5p+ promoters (purple) marked by S7p (green) 1579 
throughout differentiation. The number of promoters marked by 1580 
H3K27me3+S5p+S7p+ increases during differentiation.  1581 
E. Proportion of H3K27me3 and RNAPII-S5p promoters (purple) that are also 1582 
transcribed (gold; TPM>1). The number of actively transcribed promoters increases 1583 
during differentiation, in agreement with the increased presence of S7p.  1584 
 1585 
Figure 5. RNAPII-S5p co-localizes with H3K27me3 in terminally differentiated 1586 
neurons. 1587 
A. Schematic of gene classification according to the occupancy of H3K27me3, S5p 1588 
and S7p at promoter regions (2kb windows centered on Transcription Start Sites; 1589 
TSSs).  1590 
B. Proportion of genes with each promoter state during terminal neuronal 1591 
differentiation. Dark red: H3K27me3+ genes. 1592 
C. PRC/S5p promoters in ESCs and their promoter state in day 30 neurons. Examples 1593 
of enriched GO terms (determined using as background all PRC/S5p genes in ESCs) 1594 
and genes in each category. 1595 
D. Expression level of PRC/S5p promoters in ESCs and day 30 neurons. Acquisition 1596 
of S7p correlates with increased expression level. Genes with PRC/S5p, PRC Only or 1597 
Inactive state remain repressed in day 30 neurons. 1598 
E. Sequential ChIP (re-ChIP) was performed using day 30 neurons to test RNAPII 1599 
and H3K27me3 co-occupancy, as described in the schematic. The first ChIP with 1600 
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anti-RNAPII-S5p antibody was followed by a second ChIP using antibodies against 1601 
RNAPII-S5p (positive control), H3K27me3, RNAPII-S7p, or Digoxigenin (carry-over 1602 
negative control “Ctrl”). 1603 
F. Sequential ChIP shows RNAPII-S5p co-association with H3K27me3 at PRC/S5p 1604 
(Pitx1 and Gata4) and PRC/Active (Skap2 and Ajuba) promoters but not at Active 1605 
(Actb) or Inactive (Myf5) promoters. The mean and SD are from two biological 1606 
replicates. 1607 
  1608 
Figure 6. Increased potential for reactivation upon loss of Polycomb repression 1609 
of genes with poised PRC/S5p promoter states 1610 
A. Effect of PRC deletion in ESCs (PRC2 component EED and PRC1 component 1611 
RING1B). Barplots represent the percentage of genes in each promoter state in ESCs 1612 
that are upregulated more than 2 fold. 1613 
B. Effect of PRC2 deletion in striatal GABAergic medium spiny neurons in 6 months 1614 
old mice. Barplot represents the percentage of genes in each promoter state in day3 0 1615 
neurons that are upregulated more than 2 fold.  1616 
C. RNA levels of PRC/S5p were measured by qRT-PCR. Relative levels are 1617 
normalized to Actb internal control. Three or two biological replicates were performed 1618 
in ESC and day 3 or in day 30 neurons, respectively. Black line connects the mean 1619 
values. 1620 
 1621 
Figure 7. PRC/S5p genes that maintain their state throughout differentiation 1622 
exhibit broader distributions of H3K27me3 and poised RNAPII-S5p which 1623 
coincide with DMVs.  1624 
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A. PRC/S5p genes are kept silenced through different mechanisms during neuronal 1625 
differentiation by maintaining PRC/S5p (Always PRC/S5p; purple), resolving to PRC 1626 
Only (light blue), or resolving to Inactive (orange). Colors indicate promoter states in 1627 
each time point. 1628 
B. Average ChIP-seq enrichment plots of H3K27me3 and S5p in 10kb genomic 1629 
windows centered on transcription start site (TSS) and transcription end sites (TES), 1630 
in ESCs. 1631 
C. Average ChIP-seq enrichment plots of H3K27me3 and S5p in 10kb genomic 1632 
windows centered on TSS and TES, in day 30 neurons. 1633 
D. Boxplot of the length of the genomic regions enriched for H3K27me3 that overlap 1634 
with promoters in ESC or in day 30 neurons. The length of H3K27me3 enriched 1635 
regions covering the remaining H3K27me3+ genes are shown for comparison. P-1636 
values are calculated with Wilcoxon rank-sum test. 1637 
E. Percentage of TSS area covered by CpG islands of PRC/S5p that maintain their 1638 
state is significantly larger compared to the other gene subgroups. P-values are 1639 
calculated with Wilcoxon rank-sum test. 1640 
F. UCSC Browser tracks of genes classified in day 30 neurons as Always PRC/S5p, 1641 
PRC Only, Inactive and Active genes. First row shows methylated (gold) or 1642 
hypomethylated DNA methylation valleys (DMVs, dark blue; and smaller areas of 1643 
hypomethylated DNA, light blue) in mouse frontal cortex. 1644 
G. Proportion of promoters in the three gene groups which overlap with methylated 1645 
and hypomethylated DNA. Always PRC/S5p genes are preferentially located at 1646 
DMVs. All H3K27me3+ and Inactive genes in day 30 neurons are shown for 1647 
comparison. 1648 
 1649 
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Figure 8. Poised (PRC/S5p) genes in terminally differentiated neurons are 1650 
enriched for TFs with trans-differentiation potential.  1651 
A. Cells can trans-differentiate into other cell types by forced expression of lineage-1652 
specific TFs. The Mogrify algorithm identifies candidate TFs that drive cell-1653 
conversion as exemplified in the schematic (Rackham et al, 2016) 1654 
B. Promoter state of TFs in day 30 which are predicted by Mogrify to drive trans-1655 
differentiation towards non-neuronal or neuronal cell types. H3K27me3+ promoters 1656 
are often enriched in the Mogrify list of trans-differentiation candidates. PRC/S5p and 1657 
the PRC/Active genes are the mostly enriched promoter classes. Inactive genes are 1658 
depleted. Enrichment and depletion were tested with hypergeometric test.  1659 
C. Mogrify ranks all TFs by the likelihood to induce the conversion from cell types A 1660 
to B. By averaging these ranks, it is possible to identify those TFs most frequently 1661 
required for a conversion into a certain cell type. The ranks are used to estimate the 1662 
importance of the TF in driving the conversion.  1663 
D. TFs important for driving trans-differentiation towards different cell types were 1664 
grouped according to their promoter state and tested for enrichment in high or low 1665 
importance factors (upwards/downwards arrows). Purple and white backgrounds 1666 
correspond to enrichment tested for promoter states in day 30 or maintained along all 1667 
differentiation, respectively. Enrichment in high or low importance was tested with 1668 
Gene Set Enrichment Analysis, considered significant when False Discovery Rate 1669 
(FDR) <25%. 1670 
 1671 
 1672 
 1673 
 1674 
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Expanded View Figure Legends 1675 
 1676 
Figure EV1. Neuronal differentiation protocol starting from ESCs gives cultures 1677 
enriched for ventral midbrain dopaminergic neurons. Related to Figure 1. 1678 
A. Schematic representation of the protocols used to differentiate ESCs to 1679 
dopaminergic neurons. Time points selected for ChIP-seq and mRNA-seq are boxed.  1680 
B. Total RNA qRT-PCR shows the differential expression of specific markers during 1681 
exit from pluripotency. Relative levels are normalized to Actb and plotted as ratio to 1682 
the expression in the most expressed time point. Mean and standard deviation (SD) 1683 
are from three biological replicates.  1684 
C. Left, indirect immunofluorescence of LMX1A (green) and FOXA2 (red) in day 16 1685 
neurons. Nuclei were counterstained with DAPI (blue). Bar, 100 μm. Right, 1686 
percentage of cells positive for FOXA2, LMX1A and both. Mean and SD are from 1687 
five fields of view. 1688 
 1689 
Figure EV2. mRNA-seq profiles highlight single gene expression changes at 1690 
different stages of differentiation. Related to Fig. 1. 1691 
A. UCSC Genome Browser snapshots of mRNA-seq tracks confirm the expression of 1692 
specific markers for differentiation. ESCs progressively downregulate pluripotency 1693 
genes, such as Nanog and Oct4, and express Fgf5 at the onset of differentiation. 1694 
FoxA2 and Lmx1a are expressed in developing neurons while Th in mature 1695 
dopaminergic neurons.  1696 
B. UCSC Genome Browser snapshots of mRNA-seq tracks for additional markers of 1697 
developing (Ngn2, Nurr1, Pitx3) and mature (Aadc, Vmat, Dat) dopaminergic 1698 
neurons are sequentially activated in terminally differentiated neurons. Arrows 1699 
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represent the position of promoter and directionality of the gene. Y-axis scales are 1700 
kept constant per gene and adjusted to its maximum expression. 1701 
 1702 
Figure EV3. Functional and phenotypical characterization of neurons during 1703 
maturation from day 14 to day 30. Related to Fig. 2.  1704 
A. Spontaneous action potential firing frequency and regularity across differentiation 1705 
days. Graphs show mean and standard error of the mean (SEM) of frequency and 1706 
regularity of action potential activity across differentiation (n=3, 8, 4, 20; Frequency 1707 
ANOVA=4.371, p-value=0.2241; CV-ISI ANOVA=8.007, p-value=0.0459). 1708 
Coefficient of variation of the inter-spike-interval (CV-ISI) decreases, reflecting an 1709 
increase in regularity.  1710 
B. Example trace of spontaneous bursting in a mature neuron indicated by the 1711 
asterisk. In the lower panel, the burst is displayed over a smaller time scale to better 1712 
observe the burst properties (i.e. decline in action potential amplitude within the 1713 
burst).  1714 
C. Burst firing was only observed after 30 days in culture. Percentage of spikes per 1715 
burst and the number of spikes per burst across differentiation (n=3, 8, 5, 20; chi-1716 
squared test for trend=5.57, p-value=0.0183). d. Example trace showing spontaneous 1717 
action potential firing blocked by 1 µM Tetrodotoxin (TTX). e. Example traces of 1718 
miniature excitatory post-synaptic currents (mEPSCs) observed in the presence of 1 1719 
µM TTX. mEPSCs were blocked with 5 µM NBQX, confirming their glutamatergic 1720 
identity. f. Example traces of miniature inhibitory post-synaptic currents (mIPSCs) 1721 
observed in the presence of 1 µM TTX in the external solution and high Cl  in the 1722 
recording pipette. mIPSCs were blocked with 100 µM picrotoxin, confirming their 1723 
GABAergic identity.  1724 
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G. Confocal images showing the neuronal subtypes that are present within the 1725 
cultures. Indirect immunofluorescence of TH (green) denotes dopaminergic neurons, 1726 
VGluT2 (magenta) denotes glutamatergic neurons, and GABA (blue) denotes 1727 
GABAergic neurons, with the overlay of all channels in the bottom right panel. Bars, 1728 
30 µm.  1729 
H. UCSC Genome Browser snapshots show the expression of GABAergic and 1730 
glutamatergic neuronal markers. GABAergic and glutamatergic neurons are important 1731 
to establish neuronal circuits and ultimately to obtain functional dopaminergic 1732 
neurons. Arrows represent the position of promoter and directionality of the gene. Y-1733 
axis scales are kept constant per gene and adjusted to its maximum expression.  1734 
I. Mature neurons do not form autapses. Example trace shows a short current pulse 1735 
that evoked an action potential, but no rebound post-synaptic depolarisation. 1736 
 1737 
Figure EV4. Gene classification based on promoter association with PRC and 1738 
RNAPII at different stages of the neuronal differentiation. Related to Fig. 5.  1739 
A. Number of genes in each promoter state described in Fig. 5a. Classification based 1740 
on the presence or absence of RNAPII-S5p, -S7p and H3K27me3 at the 2kb window 1741 
centered around promoters, shown from ESC to day 30 neurons.  1742 
B. Promoter state dynamics during differentiation for all classified genes. Bottom 1743 
panel shows the promoter state dynamics for genes that are marked by H3K27me3 in 1744 
at least one time point.  1745 
C. Gene expression changes for two selected groups of genes that become Active 1746 
from Polycomb repressed states (highlighted by black boxes in panel b). Colors 1747 
indicate promoter states in each time point. In boxplots, as default of R graphics 1748 
package, box center represents the median value; box top and bottom represent third 1749 
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and first quartiles, respectively. Notches extend to ±1.58*Interquartile range (IQR)/n. 1750 
Whiskers extend to the highest point within 1.5 IQR of the third quartile and to the 1751 
lowest point within 1.5 IQR of the first quartile, respectively. Values outside whiskers 1752 
are represented as individual points. 1753 
D. Promoter state of genes that are marked by PRC in ESCs and become Active in 1754 
day 30 neurons. Examples of enriched GO terms are shown using as background all 1755 
genes. Permute p-value (GO-Elite) is shown. 1756 
 1757 
Figure EV5. Promoter state changes involving PRC loss or acquisition in 1758 
intermediate or late stages of neuronal differentiation. Related to Fig. 5.  1759 
A. Most genes that acquire H3K27me3 de novo during the early phases of 1760 
differentiation (days 1 or 3) have Active promoters in ESCs and in day 30 neurons. 1761 
Acquisition of PRC by genes with Active promoters in ESCs is accompanied by a 1762 
decrease of gene expression, as exemplified for genes that acquire H3K27me3 at day 1763 
1 and become Active again in day 30 (n=358). P-values were calculated using 1764 
Wilcoxon signed rank (paired) test.  1765 
B. Genes that acquire H3K27me3 de novo in day 16 or 30 neurons tend to have 1766 
Active promoters in ESCs. Active genes in ESCs that gain PRC in day 30 show 1767 
decreased mRNA expression (n=311). P-values were calculated using Wilcoxon 1768 
signed rank (paired) test. 1769 
 1770 
Figure EV6. Genes that maintain the PRC/S5p promoter state throughout 1771 
differentiation are often morphogenic TFs linked to different tissue identities 1772 
and show high coverage by CpG islands. Related to Figure 7. 1773 
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A. Similar low levels of mRNA expression are detected in ESC, day 16 and day 30 1774 
neurons for genes that are PRC/S5p in ESCs and remain silent through differentiation 1775 
either by retaining the PRC/S5p promoter state, or by becoming PRC Only or 1776 
Inactive. Colors indicate gene groups according to panel b.  1777 
B. Examples of enriched Gene Ontologies and associated genes of the three groups 1778 
described in panel a, using as background all genes. PRC/S5p genes that retain the 1779 
PRC/S5p state throughout differentiation include important morphogenetic TFs for 1780 
different cell lineages. Permute p-value (GO-Elite) is shown.  1781 
C. G/C composition of promoter windows for different groups of genes. Always 1782 
PRC/S5p promoters are more enriched in G/C nucleotides compared to PRC/S5p 1783 
genes that resolve to Inactive, or to the group of additional genes marked by 1784 
H3K27me3 in day 30. Inactive genes in day 30 are shown for comparison. P-values 1785 
were calculated using Wilcoxon rank sum test.  1786 
D. Overlap of CpG islands with gene bodies for different groups of genes. The gene 1787 
bodies of Always PRC/S5p are significantly more covered with CpG islands than 1788 
PRC/S5p genes that become PRC Only or Inactive, or than the group of other 1789 
H3K27me3+ genes in day 30. Inactive genes in day 30 are shown for comparison. P-1790 
values were calculated using Wilcoxon rank sum test. 1791 
 1792 
Figure EV7. Candidate genes with high influence for trans-differentiation are 1793 
associated with PRC+ promoters in dopaminergic neurons. Related to Figure 8.  1794 
A. Additional examples of day 30 promoter state enrichment in Mogrify lists of 1795 
candidate genes predicted to influence trans-differentiation towards different cell 1796 
types. Different classes of PRC+ promoters are enriched, whereas genes with Inactive 1797 
promoters are depleted. Enrichment and depletion p-values were calculated with 1798 
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hypergeometric test.  1799 
B. Mogrify identifies both the TFs with high influence to trigger change from cell 1800 
type A to cell type B and the rank order according to their predicted influence in the 1801 
conversion. Example showing that PRC/S5p and PRC/Active genes are predicted to 1802 
have higher influence in trans-differentiation towards cardiomyocyte compared to 1803 
Active or Inactive genes. Median Mogrify rank is shown in red. 1804 
 1805 
